EP0709099A3
(de)
*
|
1994-09-28 |
1996-07-24 |
Senju Pharma Co |
Wässrige Suspension zur nasalen Verabreichung enthaltend Cyclodextrin
|
ZA959469B
(en)
*
|
1994-11-15 |
1996-05-15 |
South African Druggists Ltd |
Pharmaceutical composition
|
US5468502A
(en)
*
|
1994-12-20 |
1995-11-21 |
American Home Products Corporation |
Ibuprofen enhancing solvent system
|
WO1996041646A2
(en)
*
|
1995-06-13 |
1996-12-27 |
Dyer, Alison, Margaret |
Pharmaceutical compositions containing lornoxicam and cyclodextrin
|
EP0954326B2
(de)
|
1996-04-19 |
2009-07-22 |
Grifols Inc. |
Verfahren zur inaktivierung von viren und lyophilisierung von blutproteinen
|
UA57734C2
(uk)
|
1996-05-07 |
2003-07-15 |
Пфайзер Інк. |
Комплекси включення арилгетероциклічних солей
|
US5906981A
(en)
*
|
1996-06-04 |
1999-05-25 |
Troy Corporation |
Halopropargyl inclusion complexes
|
JP4215277B2
(ja)
*
|
1996-08-09 |
2009-01-28 |
アルコン ラボラトリーズ,インコーポレイテッド |
シクロデキストリンを含有する薬学的組成物用防腐剤系
|
DE19716120A1
(de)
*
|
1997-04-17 |
1998-10-22 |
Europ Lab Molekularbiolog |
Verwendung von cholesterinsenkenden Mitteln
|
US5874418A
(en)
*
|
1997-05-05 |
1999-02-23 |
Cydex, Inc. |
Sulfoalkyl ether cyclodextrin based solid pharmaceutical formulations and their use
|
US6046177A
(en)
*
|
1997-05-05 |
2000-04-04 |
Cydex, Inc. |
Sulfoalkyl ether cyclodextrin based controlled release solid pharmaceutical formulations
|
ES2210769T3
(es)
*
|
1997-06-13 |
2004-07-01 |
Cydex Inc. |
Compuesto con vida de almacenamiento prolongada que comprende ciclodextrina y medicamentos y promedicamentos que se descomponen en componentes insolubles en agua.
|
GB9713149D0
(en)
*
|
1997-06-21 |
1997-08-27 |
Pfizer Ltd |
Pharmaceutical formulations
|
ATE323110T1
(de)
*
|
1997-07-01 |
2006-04-15 |
Pfizer Prod Inc |
Verfahren zur herstellung von einem cyclodextrin
|
CN1278269A
(zh)
*
|
1997-11-07 |
2000-12-27 |
第一制药株式会社 |
哌嗪-环糊精复合体
|
AU759280C
(en)
*
|
1998-02-23 |
2004-01-22 |
Cyclops, Ehf |
High-energy cyclodextrin complexes
|
US6699849B1
(en)
|
1998-02-23 |
2004-03-02 |
Cyclops, Ehf. |
Cyclodextrin complexes of benzodiazepines
|
CA2342797A1
(en)
*
|
1998-09-02 |
2000-03-09 |
Allergan Sales, Inc. |
Preserved cyclodextrin-containing compositions
|
FR2784584B1
(fr)
*
|
1998-10-14 |
2002-09-20 |
Adir |
Procede de preparation d'une solution pour pulverisation nasale contenant une ou plusieurs hormones sexuelles et une cyclodextrine
|
WO2000033885A1
(en)
*
|
1998-12-04 |
2000-06-15 |
California Institute Of Technology |
Supramolecular complexes containing therapeutic agents
|
US7375096B1
(en)
|
1998-12-04 |
2008-05-20 |
California Institute Of Technology |
Method of preparing a supramolecular complex containing a therapeutic agent and a multi-dimensional polymer network
|
GEP20043214B
(en)
|
1999-01-21 |
2004-04-26 |
Bristol Myers Squibb Company Us |
Complex of Ras-Farnesyltransferase Inhibitor and Sulfobutylether-7- Beta – Cyclodextrin or 2-Hydroxypropyl- Beta – Cyclodextrina and Pharmaceutical Compositions Containing the Same
|
GB9913932D0
(en)
|
1999-06-15 |
1999-08-18 |
Pfizer Ltd |
Purine derivatives
|
GB9915231D0
(en)
|
1999-06-29 |
1999-09-01 |
Pfizer Ltd |
Pharmaceutical complex
|
CA2315614C
(en)
|
1999-07-29 |
2004-11-02 |
Pfizer Inc. |
Pyrazoles
|
GB9924363D0
(en)
|
1999-10-14 |
1999-12-15 |
Pfizer Central Res |
Purine derivatives
|
GB9924361D0
(en)
|
1999-10-14 |
1999-12-15 |
Pfizer Ltd |
Purine derivatives
|
AU7937500A
(en)
*
|
1999-10-27 |
2001-05-08 |
Farmarc Nederland Bv |
Pharmaceutical composition containing midazolam
|
CA2401424C
(en)
*
|
2000-03-28 |
2011-02-08 |
Farmarc Nederland Bv |
Alprazolam inclusion complexes and pharmaceutical compositions thereof
|
WO2001082971A2
(en)
*
|
2000-05-02 |
2001-11-08 |
Theravance, Inc. |
Cyclodextrin containing glycopeptide antibiotic compositions
|
HU225810B1
(en)
|
2000-05-26 |
2007-10-29 |
Pfizer |
Therapeutically effective tropane derivatives, process for their preparation pharmaceutical compositions containing them and their use
|
US6667314B2
(en)
|
2000-05-26 |
2003-12-23 |
Pfizer, Inc. |
Tropane derivatives useful in therapy
|
US6753322B2
(en)
|
2000-06-06 |
2004-06-22 |
Pfizer Inc |
2-aminocarbonyl-9H-purine derivatives
|
US6921753B2
(en)
|
2000-06-27 |
2005-07-26 |
Pfizer Inc |
Purine derivatives
|
US6468989B1
(en)
|
2000-07-13 |
2002-10-22 |
Dow Pharmaceutical Sciences |
Gel compositions containing metronidazole
|
US6420557B1
(en)
|
2000-07-28 |
2002-07-16 |
Pfizer Inc. |
Crystalline therapeutic agent
|
US8980290B2
(en)
|
2000-08-03 |
2015-03-17 |
Antares Pharma Ipl Ag |
Transdermal compositions for anticholinergic agents
|
US7198801B2
(en)
|
2000-08-03 |
2007-04-03 |
Antares Pharma Ipl Ag |
Formulations for transdermal or transmucosal application
|
US7214381B2
(en)
*
|
2000-08-03 |
2007-05-08 |
Antares Pharma Ipl Ag |
Composition for transdermal and/or transmucosal administration of active compounds that ensures adequate therapeutic levels
|
PE20020300A1
(es)
*
|
2000-08-22 |
2002-05-10 |
Pharmacia Corp |
Composicion de solucion de un farmaco antibiotico a base de oxazolidinona con mejoramiento de la carga de farmaco
|
GB0022695D0
(en)
|
2000-09-15 |
2000-11-01 |
Pfizer Ltd |
Purine Derivatives
|
PE20020578A1
(es)
|
2000-10-10 |
2002-08-14 |
Upjohn Co |
Una composicion de antibiotico topico para el tratamiento de infecciones oculares
|
US6548508B2
(en)
|
2000-10-20 |
2003-04-15 |
Pfizer, Inc. |
Use of PDE V inhibitors for improved fecundity in mammals
|
US6566556B2
(en)
*
|
2000-12-19 |
2003-05-20 |
Nippon Shokubai Co., Ltd. |
Method for production of alkanolamine and apparatus therefor
|
JP2005503446A
(ja)
|
2001-01-11 |
2005-02-03 |
イーストマン ケミカル カンパニー |
シクロデキストリンスルホネート、ゲスト包接錯体、その製造方法及び関連物質
|
US20020146409A1
(en)
*
|
2001-01-30 |
2002-10-10 |
Herring Steven W. |
Methods for stabilizing lyophilized blood proteins
|
IL141647A0
(en)
*
|
2001-02-26 |
2002-03-10 |
Yeda Res & Dev |
Synthetic human peptides and pharmaceutical compositions comprising them for the treatment of systemic lupus erythematosus
|
US6579898B2
(en)
|
2001-03-01 |
2003-06-17 |
Pfizer Inc. |
Compositions having improved bioavailability
|
US7034013B2
(en)
*
|
2001-03-20 |
2006-04-25 |
Cydex, Inc. |
Formulations containing propofol and a sulfoalkyl ether cyclodextrin
|
ATE556059T1
(de)
|
2001-04-10 |
2012-05-15 |
Pfizer |
Pyrazolderivate zur behandlung von hiv
|
GEP20053654B
(en)
*
|
2001-05-01 |
2005-11-10 |
Pfizer Prod Inc |
Method For Manufacturing Low Dose Pharmaceutical Composition Having Uniform Drug Distribution
|
US7595378B2
(en)
|
2001-06-13 |
2009-09-29 |
Genmab A/S |
Human monoclonal antibodies to epidermal growth factor receptor (EGFR)
|
EP1269994A3
(de)
*
|
2001-06-22 |
2003-02-12 |
Pfizer Products Inc. |
Pharmazeutische Zusammensetzungen die ein Arzneimittel und die Konzentration verbesserende Polymere enthalten
|
WO2003002153A1
(en)
*
|
2001-06-28 |
2003-01-09 |
Wyeth |
Composition and method for reducing adverse interactions between phenothiazine derivatives and plasma using cyclodextrins
|
MXPA03011793A
(es)
*
|
2001-06-29 |
2004-04-02 |
Maxygen Holdings Ltd |
Formulaciones de interferon.
|
GB0116453D0
(en)
|
2001-07-05 |
2001-08-29 |
Imp College Innovations Ltd |
Method
|
US20040198698A1
(en)
*
|
2001-07-20 |
2004-10-07 |
Walter Heinzelmann |
Nitrate ester-cyclodextrin complexes
|
US6653339B2
(en)
|
2001-08-15 |
2003-11-25 |
Pfizer Inc. |
Method of treating irritable bowel syndrome
|
US7141540B2
(en)
*
|
2001-11-30 |
2006-11-28 |
Genta Salus Llc |
Cyclodextrin grafted biocompatible amphilphilic polymer and methods of preparation and use thereof
|
GB0129273D0
(en)
|
2001-12-06 |
2002-01-23 |
Pfizer Ltd |
Crystalline drug form
|
US6881726B2
(en)
|
2001-12-24 |
2005-04-19 |
Dow Pharmaceutical Sciences |
Aqueous compositions containing metronidazole
|
BR0307332A
(pt)
|
2002-02-01 |
2004-12-07 |
Pfizer Prod Inc |
Formas de dosagem farmacêuticas de liberação controlada de um inibidor da proteìna de transferência do éster de colesterol
|
US6756392B2
(en)
|
2002-02-11 |
2004-06-29 |
Pfizer Inc |
Nicotinamide derivatives useful as PDE4 inhibitors
|
NZ534197A
(en)
|
2002-02-11 |
2007-01-26 |
Pfizer |
Nicotinamide derivatives useful as PDE4 inhibitors
|
CA2477049A1
(en)
*
|
2002-02-22 |
2003-09-04 |
Pharmacia Corporation |
Ophthalmic antibiotic drug formulations containing a cyclodextrin compound and cetyl pyridinium chloride
|
MXPA04008171A
(es)
*
|
2002-02-22 |
2004-11-26 |
Pharmacia Corp |
Formulacion oftalmica con sistema de goma.
|
GB0207104D0
(en)
|
2002-03-26 |
2002-05-08 |
Pfizer Ltd |
Stable hydrate of a muscarinic receptor antagonist
|
US6855724B2
(en)
|
2002-04-08 |
2005-02-15 |
Agouron Pharmaceuticals, Inc. |
Tropane derivatives useful in therapy
|
GB0209022D0
(en)
|
2002-04-19 |
2002-05-29 |
Imp College Innovations Ltd |
Compounds
|
US6869939B2
(en)
*
|
2002-05-04 |
2005-03-22 |
Cydex, Inc. |
Formulations containing amiodarone and sulfoalkyl ether cyclodextrin
|
US6818662B2
(en)
*
|
2002-05-28 |
2004-11-16 |
Taisho Pharmaceutical Co., Ltd. |
Pharmaceutical composition
|
GB0212749D0
(en)
*
|
2002-06-01 |
2002-07-10 |
Boots Co Plc |
Personal care compositions
|
PL212428B1
(pl)
*
|
2002-08-20 |
2012-09-28 |
Bristol Myers Squibb Co |
Kompleks aripiprazolu, preparat farmaceutyczny zawierajacy ten kompleks i jego zastosowanie
|
GB0219961D0
(en)
|
2002-08-28 |
2002-10-02 |
Pfizer Ltd |
Oxytocin inhibitors
|
CA2497792C
(en)
|
2002-09-06 |
2014-08-05 |
Insert Therapeutics, Inc. |
Cyclodextrin-based polymers for therapeutics delivery
|
GB0221169D0
(en)
|
2002-09-12 |
2002-10-23 |
Univ Bath |
Crystal
|
AU2003275329B2
(en)
*
|
2002-09-13 |
2008-04-03 |
Cydex Pharmaceuticals, Inc. |
Capsules containing aqueous fill compositions stabilized with derivatized cyclodextrin
|
US20040058895A1
(en)
*
|
2002-09-18 |
2004-03-25 |
Bone Care International, Inc. |
Multi-use vessels for vitamin D formulations
|
US7148211B2
(en)
*
|
2002-09-18 |
2006-12-12 |
Genzyme Corporation |
Formulation for lipophilic agents
|
US7230025B2
(en)
|
2002-09-26 |
2007-06-12 |
Pfizer, Inc. |
Pyrazole derivatives
|
US6933312B2
(en)
|
2002-10-07 |
2005-08-23 |
Agouron Pharmaceuticals, Inc. |
Pyrazole derivatives
|
IL152573A
(en)
*
|
2002-10-31 |
2009-11-18 |
Transpharma Medical Ltd |
A system for the transmission through the skin of a medical preparation against vomiting and nausea
|
IL152575A
(en)
*
|
2002-10-31 |
2008-12-29 |
Transpharma Medical Ltd |
A skin-to-skin transmission system of water-insoluble drugs
|
US7323462B2
(en)
|
2002-12-10 |
2008-01-29 |
Pfizer Inc. |
Morpholine dopamine agonists
|
JP2006511606A
(ja)
|
2002-12-13 |
2006-04-06 |
ワーナー−ランバート・カンパニー、リミテッド、ライアビリティ、カンパニー |
下部尿路症状を治療するα−2−δリガンド
|
CA2451267A1
(en)
|
2002-12-13 |
2004-06-13 |
Warner-Lambert Company Llc |
Pharmaceutical uses for alpha2delta ligands
|
JP4817068B2
(ja)
*
|
2003-01-14 |
2011-11-16 |
イエダ・リサーチ・アンド・ディベロップメント・カンパニー・リミテッド |
全身性エリテマトーデスの治療のためのペプチドの非経口製剤
|
BRPI0406737A
(pt)
|
2003-01-14 |
2005-12-20 |
Teva Pharma |
Formulações parenterais de um peptìdeo para o tratamento de eritomatose sistêmica de lupus
|
EP1460064A1
(de)
|
2003-03-14 |
2004-09-22 |
Pfizer Limited |
Indole-2-carboxamide als beta-2 Agonisten
|
WO2004091630A1
(ja)
*
|
2003-04-18 |
2004-10-28 |
Advanced Medicine Research Institute |
眼に適用する疾患治療剤
|
CL2004000826A1
(es)
|
2003-04-25 |
2005-03-04 |
Pfizer |
Uso de un agonista para el receptor 5-ht2c para preparar un medicamento util en el tratamiento de la incontinencia urinaria provocada por estres, con la condicion de que el agonista no sea 1-[6-cloro-5-(trifluorometil)-2-piridinil]piperazina (org-129
|
US7157446B2
(en)
*
|
2003-05-02 |
2007-01-02 |
Bristol Myers Squibb Company |
Complex of ras-farnesyltransferase inhibitor, a cyclodextrin, and ethanol
|
US7268147B2
(en)
|
2003-05-15 |
2007-09-11 |
Pfizer Inc |
Compounds useful for the treatment of diseases
|
OA13248A
(en)
|
2003-09-03 |
2007-01-31 |
Pfizer |
Benzimidazolone coumpounds having 5-HT4 receptor agonistic activity.
|
ATE450535T1
(de)
|
2003-09-03 |
2009-12-15 |
Glaxo Group Ltd |
Neues verfahren zur herstellung von pleuromutilinderivaten
|
US7220772B2
(en)
|
2003-09-05 |
2007-05-22 |
Pfizer, Inc. |
Pyrazole derivatives
|
US6960300B2
(en)
*
|
2003-09-08 |
2005-11-01 |
Sami Labs Limited |
Process for preparing water soluble diterpenes and their applications
|
WO2005025675A1
(en)
|
2003-09-12 |
2005-03-24 |
Pfizer Limited |
Combinations comprising alpha-2-delta ligands and serotonin / noradrenaline re-uptake inhibitors
|
US7309790B2
(en)
|
2003-10-03 |
2007-12-18 |
Pfizer Inc |
Chemical compounds
|
ATE534373T1
(de)
|
2003-10-10 |
2011-12-15 |
Antares Pharma Ipl Ag |
Transdermale pharmazeutische formulierung zur minimierung von rückständen auf der haut
|
TW200517114A
(en)
|
2003-10-15 |
2005-06-01 |
Combinatorx Inc |
Methods and reagents for the treatment of immunoinflammatory disorders
|
US7129042B2
(en)
*
|
2003-11-03 |
2006-10-31 |
Diagnostic Hybrids, Inc. |
Compositions and methods for detecting severe acute respiratory syndrome coronavirus
|
WO2005051293A2
(en)
|
2003-11-21 |
2005-06-09 |
Combinatorx, Incorporated |
Methods and reagents for the treatment of inflammatory disorders
|
US20070020299A1
(en)
*
|
2003-12-31 |
2007-01-25 |
Pipkin James D |
Inhalant formulation containing sulfoalkyl ether cyclodextrin and corticosteroid
|
US20070020196A1
(en)
*
|
2003-12-31 |
2007-01-25 |
Pipkin James D |
Inhalant formulation containing sulfoalkyl ether cyclodextrin and corticosteroid prepared from a unit dose suspension
|
KR20070007075A
(ko)
*
|
2003-12-31 |
2007-01-12 |
사이덱스 인크 |
술포알킬 에테르 시클로덱스트린 및 코르티코스테로이드를함유한 흡입용 제형
|
OA13362A
(en)
|
2004-01-22 |
2007-04-13 |
Pfizer |
Sulfonamide derivatives for the treatment of diseases.
|
ES2289691T3
(es)
|
2004-01-22 |
2008-02-01 |
Pfizer, Inc. |
Derivados de sulfonamida para el tratamiento de enfermedades.
|
US7629358B2
(en)
|
2004-03-17 |
2009-12-08 |
Pfizer Inc |
Compounds useful for the treatment of diseases
|
US7687533B2
(en)
|
2004-03-18 |
2010-03-30 |
Pfizer Inc. |
N-(1-arylpyrazol-4l) sulfonamides and their use as parasiticides
|
US7538141B2
(en)
|
2004-03-23 |
2009-05-26 |
Alan Daniel Brown |
Compounds for the treatment of diseases
|
BRPI0507877A
(pt)
|
2004-03-23 |
2007-07-24 |
Pfizer |
derivados de formamida, composição farmacêutica, uso dos mesmos e combinação
|
US8198270B2
(en)
*
|
2004-04-15 |
2012-06-12 |
Onyx Therapeutics, Inc. |
Compounds for proteasome enzyme inhibition
|
PL1745064T3
(pl)
|
2004-04-15 |
2011-06-30 |
Onyx Therapeutics Inc |
Związki do hamowania enzymu proteazomu
|
US20050234018A1
(en)
*
|
2004-04-15 |
2005-10-20 |
Allergan, Inc. |
Drug delivery to the back of the eye
|
CA2562585A1
(en)
|
2004-04-23 |
2005-11-10 |
Cydex, Inc. |
Dpi formulation containing sulfoalkyl ether cyclodextrin
|
EP1745029A1
(de)
|
2004-04-30 |
2007-01-24 |
Warner-Lambert Company LLC |
Substituierte morpholinverbindungen zur behandlung von erkrankungen des zentralen nervensystems
|
WO2005117911A2
(en)
*
|
2004-05-06 |
2005-12-15 |
Cydex, Inc. |
Taste-masked formulations containing sertraline and sulfoalkyl ether cyclodextrin
|
US7456164B2
(en)
|
2004-05-07 |
2008-11-25 |
Pfizer, Inc |
3- or 4-monosubtituted phenol and thiophenol derivatives useful as H3 ligands
|
CN101014612B
(zh)
*
|
2004-05-10 |
2014-11-26 |
欧尼斯治疗公司 |
用于酶抑制的化合物
|
EP1595881A1
(de)
|
2004-05-12 |
2005-11-16 |
Pfizer Limited |
Tetrahydronaphthyridin-Derivate, verwendbar als Histamin H3 Rezeptor-Liganden
|
EA200801608A1
(ru)
|
2004-06-15 |
2008-10-30 |
Пфайзер Инк. |
Производные бензимидазолонкарбоновой кислоты
|
US7737163B2
(en)
|
2004-06-15 |
2010-06-15 |
Pfizer Inc. |
Benzimidazolone carboxylic acid derivatives
|
WO2006018718A2
(en)
|
2004-08-12 |
2006-02-23 |
Pfizer Limited |
Triazolopyridinylsulfanyl derivatives as p38 map kinase inhibitors
|
CN101023064B
(zh)
|
2004-08-26 |
2011-02-16 |
辉瑞大药厂 |
作为蛋白激酶抑制剂的对映异构体纯的氨基杂芳基化合物
|
ITMI20041763A1
(it)
*
|
2004-09-16 |
2004-12-16 |
Altergon Sa |
Nuove formulazioni iniettabili contenenti progesterone
|
ATE417830T1
(de)
|
2004-11-02 |
2009-01-15 |
Pfizer |
Sulfonylbenzimidazolderivate
|
US9120774B2
(en)
|
2004-11-03 |
2015-09-01 |
University Of Kansas |
Novobiocin analogues having modified sugar moieties
|
GT200500317A
(es)
*
|
2004-11-05 |
2006-10-27 |
|
Proceso para preparar compuestos de quinolina y productos obtenidos de los mismos
|
US20060105992A1
(en)
*
|
2004-11-08 |
2006-05-18 |
Buchanan Charles M |
Pharmaceutical formulations of cyclodextrins and selective estrogen receptor modulator compounds
|
US20060105045A1
(en)
*
|
2004-11-08 |
2006-05-18 |
Buchanan Charles M |
Cyclodextrin solubilizers for liquid and semi-solid formulations
|
CN102847136A
(zh)
*
|
2004-12-07 |
2013-01-02 |
普罗特奥里克斯公司 |
抑制蛋白酶体的组合物
|
EP1674098A1
(de)
|
2004-12-23 |
2006-06-28 |
Schering Aktiengesellschaft |
Stabile, unbedenkliche parenterale Formulierungen von hochreaktiven organischen Arzneimitteln mit niedriger oder keiner wässrigen Löslichkeit
|
US8703099B2
(en)
|
2005-02-24 |
2014-04-22 |
Dr Pharma Nova, Llc |
Registry method and control system for DEA schedule II-V medicines
|
MX2007011498A
(es)
|
2005-03-17 |
2007-10-11 |
Pfizer |
Derivados de n-(n-sulfonilaminometil)ciclopropanocarboxamida utiles para el tratamiento de dolor.
|
ES2313626T3
(es)
|
2005-03-21 |
2009-03-01 |
Pfizer Limited |
Derivados de triazol sustituidos como antagonistas de oxitocina.
|
DE602006019074D1
(de)
*
|
2005-04-15 |
2011-02-03 |
Einstein Coll Med |
Vitamin k zur vorbeugung und behandlung von hautausschlag infolge einer anti-egfr-therapie
|
EP1874331B1
(de)
|
2005-04-19 |
2014-09-03 |
Kings College London |
Verwendung von bip gegen knochenverlust und osteoporose
|
WO2007124250A2
(en)
|
2006-04-21 |
2007-11-01 |
Antares Pharma Ipl Ag |
Methods of treating hot flashes with formulations for transdermal or transmucosal application
|
US20060258712A1
(en)
*
|
2005-04-24 |
2006-11-16 |
Wyeth |
Methods for modulating bladder function
|
AU2006242920A1
(en)
|
2005-05-04 |
2006-11-09 |
Pfizer Limited |
2-amido-6-amino-8-oxopurine derivatives as Toll-Like receptor modulators for the treatment of cancer and viral infections, such as hepatitis C
|
ES2393768T3
(es)
|
2005-05-26 |
2012-12-27 |
Neuron Systems, Inc |
Derivado de quinolina para el tratamiento de enfermedades retinianas
|
WO2006125642A1
(en)
|
2005-05-27 |
2006-11-30 |
Antares Pharma Ipl Ag |
Methods and apparatus for transdermal or transmucosal application of testosterone
|
EP1903039A4
(de)
*
|
2005-06-13 |
2010-09-22 |
Takeda Pharmaceutical |
Injektion
|
US20080176865A1
(en)
*
|
2005-06-15 |
2008-07-24 |
Pfizer Limited |
Substituted arylpyrazoles
|
DE602006012042D1
(de)
|
2005-06-15 |
2010-03-18 |
Pfizer Ltd |
Substituierte arylpyrazole zur verwendung gegen parasiten
|
US7645786B2
(en)
|
2005-06-15 |
2010-01-12 |
Pfizer Inc. |
Substituted arylpyrazoles
|
US20080146643A1
(en)
*
|
2005-06-15 |
2008-06-19 |
Pfizer Limited |
Combination
|
AR054849A1
(es)
*
|
2005-07-26 |
2007-07-18 |
Wyeth Corp |
Diazepinoquinolinas, sintesis de las mismas, e intermediarios para obtenerlas
|
US20070191306A1
(en)
*
|
2005-08-17 |
2007-08-16 |
Bristol-Myers Squibb Company |
FACTOR Xa INHIBITOR FORMULATION AND METHOD
|
DE102005041860A1
(de)
*
|
2005-09-02 |
2007-03-08 |
Schering Ag |
Nanopartikulärer Einschluss- und Ladungskomplex für pharmazeutische Formulierungen
|
US20100204178A1
(en)
*
|
2006-10-02 |
2010-08-12 |
James Cloyd |
Novel parenteral carbamazepine formulation
|
EP1928464B1
(de)
|
2005-09-30 |
2014-05-14 |
Lundbeck Inc. |
Neue parenterale carbamazepin-formulierung
|
US7629331B2
(en)
|
2005-10-26 |
2009-12-08 |
Cydex Pharmaceuticals, Inc. |
Sulfoalkyl ether cyclodextrin compositions and methods of preparation thereof
|
DK2581078T3
(en)
|
2005-10-26 |
2015-03-02 |
Cydex Pharmaceuticals Inc |
Sulfoalkylætercyclodekstrinsammensætninger and processes for the preparation thereof
|
US8716322B2
(en)
|
2005-11-09 |
2014-05-06 |
Onyx Therapeutics, Inc. |
Compounds for enzyme inhibition
|
EP1959966B1
(de)
|
2005-11-28 |
2020-06-03 |
Marinus Pharmaceuticals, Inc. |
Ganaxolon-formulierungen und verfahren zu ihrer herstellung und verwendung
|
US20070135586A1
(en)
*
|
2005-12-09 |
2007-06-14 |
Shreyas Chakravarti |
Polyamide blend compositions formed article and process thereof
|
US20070160542A1
(en)
*
|
2005-12-20 |
2007-07-12 |
Verus Pharmaceuticals, Inc. |
Methods and systems for the delivery of corticosteroids having an enhanced pharmacokinetic profile
|
US20070197486A1
(en)
*
|
2005-12-20 |
2007-08-23 |
Verus Pharmaceuticals, Inc. |
Methods and systems for the delivery of corticosteroids
|
US20070185066A1
(en)
*
|
2005-12-20 |
2007-08-09 |
Verus Pharmaceuticals, Inc. |
Systems and methods for the delivery of corticosteroids
|
NL2000323C2
(nl)
|
2005-12-20 |
2007-11-20 |
Pfizer Ltd |
Pyrimidine-derivaten.
|
JP2009520827A
(ja)
*
|
2005-12-20 |
2009-05-28 |
ティカ レーケメデル アーベー |
肺内沈着の増大を有するコルチコステロイドを送達するためのシステムおよび方法
|
US20070178049A1
(en)
*
|
2005-12-20 |
2007-08-02 |
Verus Pharmaceuticals, Inc. |
Systems and methods for the delivery of corticosteroids having an enhanced pharmacokinetic profile
|
US20070249572A1
(en)
*
|
2005-12-20 |
2007-10-25 |
Verus Pharmaceuticals, Inc. |
Systems and methods for the delivery of corticosteroids
|
US20070141684A1
(en)
|
2005-12-21 |
2007-06-21 |
Pfizer Inc |
Preparation of gamma-amino acids having affinity for the alpha-2-delta protein
|
GB0600406D0
(en)
|
2006-01-10 |
2006-02-15 |
Univ Bath |
Crystal
|
TW200734334A
(en)
*
|
2006-01-13 |
2007-09-16 |
Wyeth Corp |
Treatment of substance abuse
|
GB0600928D0
(en)
|
2006-01-17 |
2006-02-22 |
Novacta Biosystems Ltd |
Improvements relating to lantibiotics
|
US20070191599A1
(en)
*
|
2006-02-15 |
2007-08-16 |
Verus Pharmaceuticals, Inc. |
Methods of manufacturing cortiscosteroid solutions
|
US20070225278A1
(en)
*
|
2006-03-24 |
2007-09-27 |
Wyeth |
Methods for treating cognitive and other disorders
|
TW200806299A
(en)
*
|
2006-03-24 |
2008-02-01 |
Wyeth Corp |
Treatment of pain
|
MX2008012105A
(es)
*
|
2006-03-24 |
2008-10-03 |
Wyeth Corp |
Metodos para modular la funcion de la vejiga.
|
AU2007231011A1
(en)
*
|
2006-03-24 |
2007-10-04 |
Wyeth |
New therapeutic combinations for the treatment of depression
|
PE20080172A1
(es)
*
|
2006-03-24 |
2008-04-21 |
Wyeth Corp |
Compuestos dihidrobenzofuranil alcanamida como moduladores del receptor 5-ht2c
|
US20070238789A1
(en)
*
|
2006-03-31 |
2007-10-11 |
Chin-Ming Chang |
Prednisolone acetate compositions
|
MX2008013407A
(es)
*
|
2006-04-18 |
2009-03-09 |
Ekr Therapeutics Inc |
Composiciones de bolo iv premezcladas, listas para uso y metodos de uso.
|
CN100374468C
(zh)
*
|
2006-05-25 |
2008-03-12 |
重庆通量精细化工有限公司 |
水溶性磺烷基醚-β-环糊精的合成工艺
|
NZ573759A
(en)
*
|
2006-06-19 |
2012-03-30 |
Proteolix Inc |
Peptide epoxyketones for proteasome inhibition
|
EP2043685B1
(de)
*
|
2006-07-03 |
2015-12-23 |
Genmab A/S |
Prävention von hautausschlag bei patienten in anti-egfr-therapie
|
AR061889A1
(es)
|
2006-07-13 |
2008-10-01 |
Medichem Sa |
Proceso mejorado para la preparacion de voriconazol
|
GB2453475B
(en)
|
2006-07-25 |
2011-01-19 |
Secr Defence |
Live vaccine strain
|
US20100022481A1
(en)
*
|
2006-08-02 |
2010-01-28 |
Dong Wang |
Drug Carriers, Their Synthesis, and Methods of Use Thereof
|
US20080207731A1
(en)
|
2006-08-23 |
2008-08-28 |
Intellect Neurosciences, Inc. |
3-(3-indolyl) propionic acid calcium salt and method of making 3-(3-indolyl) propionic acid free acid therefrom
|
US20090239942A1
(en)
*
|
2006-09-15 |
2009-09-24 |
Cloyd James C |
Topiramate Compositions and Methods of Making and Using the Same
|
EP2380566A3
(de)
|
2006-09-15 |
2012-04-11 |
Stevia APS |
Verwendung von Steviol oder Isosteviol in der Behandlung von Insulinresistenz oder von mit Insulinresistenz assoziierten Krankheiten
|
DK2061458T3
(en)
*
|
2006-09-15 |
2015-03-09 |
Univ Minnesota |
Topiramate compositions and methods for their use
|
CA2657550C
(en)
|
2006-09-21 |
2011-11-01 |
Raqualia Pharma Inc. |
Benzimidazole derivatives as selective acid pump inhibitors
|
MX2009003542A
(es)
|
2006-10-12 |
2009-04-15 |
Wyeth Corp |
Metodos y composiciones con opalescencia reducida.
|
EA015488B1
(ru)
|
2006-10-18 |
2011-08-30 |
Пфайзер Продактс Инк. |
Содержащие диариловый эфир соединения мочевины
|
WO2008067027A2
(en)
|
2006-10-20 |
2008-06-05 |
Icos Corporation |
Compositions of chkl inhibitors and cyclodextrin
|
WO2008050199A2
(en)
|
2006-10-23 |
2008-05-02 |
Pfizer Japan Inc. |
Substituted phenylmethyl bicyclocarboxyamide compounds
|
US8158609B1
(en)
*
|
2006-11-02 |
2012-04-17 |
Novartis Ag |
Use of cyclodextrins as an active ingredient for treating dry AMD and solubilizing drusen
|
WO2008055260A2
(en)
|
2006-11-03 |
2008-05-08 |
Wyeth |
Glycolysis-inhibiting substances in cell culture
|
KR100822133B1
(ko)
*
|
2006-11-06 |
2008-04-15 |
한미약품 주식회사 |
비타민 d 또는 이의 유도체의 고체분산체 및비스포스포네이트를 포함하는, 골다공증 예방 또는 치료용복합제제
|
US20100056500A1
(en)
*
|
2006-11-21 |
2010-03-04 |
Thitiwan Buranachokaisan |
Stable Parenteral Formulation
|
US20080176958A1
(en)
|
2007-01-24 |
2008-07-24 |
Insert Therapeutics, Inc. |
Cyclodextrin-based polymers for therapeutics delivery
|
EP2131849B1
(de)
*
|
2007-03-02 |
2011-10-26 |
The University Of Wollongong |
Zusammensetzungen und verfahren zur abgabe von mitteln gegen krebs
|
EP2115126B1
(de)
|
2007-03-02 |
2015-04-08 |
Wyeth LLC |
Verwendung von kupfer und glutamat in zellkulturen zur herstellung von polypeptiden
|
MX2009011619A
(es)
*
|
2007-04-27 |
2010-01-18 |
Cydex Pharmaceuticals Inc |
Formulaciones que contienen clopidogrel y eter sulfoalquilico-ciclodextrina y metodos de uso.
|
AU2015255164B2
(en)
*
|
2007-04-27 |
2017-06-08 |
Cydex Pharmaceuticals, Inc. |
Formulations containing clopidogrel and sulfoalkyl ether cyclodextrin and methods of use
|
US7960353B2
(en)
*
|
2007-05-10 |
2011-06-14 |
University Of Kansas |
Novobiocin analogues as neuroprotective agents and in the treatment of autoimmune disorders
|
CA2687944A1
(en)
*
|
2007-05-24 |
2008-11-27 |
Pfizer Limited |
Spirocyclic quinazoline derivatives and their use as pde7 inhibitors
|
JP5250026B2
(ja)
|
2007-05-25 |
2013-07-31 |
イプセン ファルマ ソシエテ パール アクシオン サンプリフィエ |
ヒダントインで修飾したメラノコルチン受容体リガンド
|
ES2493641T3
(es)
*
|
2007-06-28 |
2014-09-12 |
Cydex Pharmaceuticals, Inc. |
Administración nasal de soluciones acuosas de corticosteroides
|
TWI428132B
(zh)
|
2007-07-02 |
2014-03-01 |
Lilly Co Eli |
癌症化療效果之強化
|
GB0714030D0
(en)
|
2007-07-18 |
2007-08-29 |
Novacta Biosystems Ltd |
The use of type-B lantibiotic-based compounds having antimicrobial activity
|
GB0714029D0
(en)
|
2007-07-18 |
2007-08-29 |
Novacta Biosystems Ltd |
Lantibiotic-based compounds having antimicrobial activity
|
US8193181B2
(en)
|
2007-09-05 |
2012-06-05 |
Rigel Pharmaceuticals, Inc. |
Xinafoate salt of N4-(2,2-difluoro-4H-benzo[1,4]oxazin-3-one)-6-yl]-5-fluoro-N2-[3-(methylaminocarbonylmethyleneoxy) phenyl]2,4-pyrimidinediamine
|
KR100929920B1
(ko)
*
|
2007-09-05 |
2009-12-04 |
주식회사 마크로케어 |
사이클로덱스트린 및 이의 유도체에 소수성 생리활성성분이 포접된 포접체의 제조방법 및 이로써 제조된포접체의 용도
|
CL2008002777A1
(es)
*
|
2007-09-21 |
2010-01-22 |
Wyeth Corp |
Metodo de preparacion de compuestos diazepinoquinolinicos quirales por recristalizacion en un sistema de solvente ternario.
|
MY166950A
(en)
|
2007-10-04 |
2018-07-25 |
Onyx Therapeutics Inc |
Crystalline peptide epoxy ketone protease inhibitors and the synthesis of amino acid keto-epoxides
|
EP2057982A1
(de)
|
2007-11-09 |
2009-05-13 |
Archimedes Development Limited |
Intranasale Zusammensetzungen
|
US8054177B2
(en)
*
|
2007-12-04 |
2011-11-08 |
Avaya Inc. |
Systems and methods for facilitating a first response mission at an incident scene using patient monitoring
|
US8192721B2
(en)
*
|
2007-12-13 |
2012-06-05 |
Verrow Pharmaceuticals, Inc. |
Compositions useful for reducing toxicity associated with gadolinium-based contrast agents
|
US8815953B2
(en)
*
|
2008-03-13 |
2014-08-26 |
Spectrum Pharmaceuticals, Inc. |
Formulations of vitamin K analogs for topical use
|
GB2458473A
(en)
|
2008-03-17 |
2009-09-23 |
Imuthes Ltd |
3'-O-allyl- and 3'-O-carboxymethyl- 2'-aminosaccharide derivatives, & amides thereof with peptides, as adjuvants
|
US7635773B2
(en)
|
2008-04-28 |
2009-12-22 |
Cydex Pharmaceuticals, Inc. |
Sulfoalkyl ether cyclodextrin compositions
|
WO2009137611A2
(en)
*
|
2008-05-06 |
2009-11-12 |
Board Of Regents, The University Of Texas System |
Treatment of pulmonary fungal infection with voriconazole via inhalation
|
US20110144202A1
(en)
*
|
2008-06-16 |
2011-06-16 |
Uwe Marx |
Concentrated oxaliplatin solution and its method of preparation
|
WO2010014617A1
(en)
*
|
2008-07-28 |
2010-02-04 |
University Of Kansas |
Heat shock protein 90 inhibitor dosing methods
|
US8518952B2
(en)
|
2008-08-06 |
2013-08-27 |
Pfizer Inc. |
6 substituted 2-heterocyclylamino pyrazine compounds as CHK-1 inhibitors
|
EP2163253B1
(de)
|
2008-09-15 |
2013-07-17 |
ULLRICH, Oliver |
Extrakte von der Pflanze Hornstedtia scyphifera und deren immunsuppressive Wirkungen
|
US20100093872A1
(en)
*
|
2008-10-15 |
2010-04-15 |
Erimos Pharmaceuticals Llc |
Stable aqueous formulations of water insoluble or poorly soluble drugs
|
EP2349313A4
(de)
|
2008-10-21 |
2012-08-29 |
Onyx Therapeutics Inc |
Kombinationstherapie mit peptidepoxyketonen
|
US10463677B2
(en)
|
2008-11-07 |
2019-11-05 |
Cydex Pharmaceuticals, Inc. |
Composition containing sulfoalkyl ether cyclodextrin and latanoprost
|
UA102709C2
(uk)
|
2008-11-15 |
2013-08-12 |
Ріб-Екс Фармасьютікалз, Інк. |
Протимікробна композиція
|
US8252790B2
(en)
|
2008-11-21 |
2012-08-28 |
Raqualia Pharma Inc. |
Pyrazole-3-carboxamide derivative having 5-HT2B receptor antagonist activity
|
JP2012512261A
(ja)
|
2008-12-17 |
2012-05-31 |
ジェネンテック, インコーポレイテッド |
C型肝炎ウイルス併用療法
|
HUE025013T2
(hu)
|
2009-01-12 |
2016-04-28 |
Pfizer Ltd |
Szulfonamid-származékok
|
RS53586B1
(en)
|
2009-01-14 |
2015-02-27 |
Novacta Biosystems Limited |
DERIVATION OF DECISION
|
GB0900599D0
(en)
|
2009-01-14 |
2009-02-18 |
Novacta Biosystems Ltd |
Treatment
|
EA020733B1
(ru)
|
2009-02-04 |
2015-01-30 |
Новакта Биосистемс Лимитед |
Производные актагардина
|
US8828937B2
(en)
|
2009-03-12 |
2014-09-09 |
Haase Investments Ug |
Bone morphogenetic protein 2 (BMP2) variants with reduced BMP antagonist sensitivity
|
AR075899A1
(es)
|
2009-03-20 |
2011-05-04 |
Onyx Therapeutics Inc |
Tripeptidos epoxicetonas cristalinos inhibidores de proteasa
|
EP2233502A1
(de)
|
2009-03-27 |
2010-09-29 |
Deutsches Rheuma-Forschungszentrum Berlin |
Sialylierte antigenspezifische Antikörper zur Behandlung oder Vorbeugung von ungewollten entzündlichen Immunreaktionen und Verfahren zu deren Herstellung
|
WO2010116270A1
(en)
|
2009-04-10 |
2010-10-14 |
Pfizer Inc. |
Ep2/4 agonists
|
GB0906234D0
(en)
|
2009-04-14 |
2009-05-20 |
Secr Defence |
Vaccine
|
WO2010132711A1
(en)
|
2009-05-13 |
2010-11-18 |
Cydex Pharmaceuticals, Inc. |
Pharmaceutical compositions comprising prasugrel and cyclodextrin derivatives and methods of making and using the same
|
ES2767880T3
(es)
|
2009-05-29 |
2020-06-18 |
Cydex Pharmaceuticals Inc |
Composiciones inyectables de melfalán que comprenden un derivado de ciclodextrina y métodos de preparación y uso de las mismas
|
US11020363B2
(en)
|
2009-05-29 |
2021-06-01 |
Cydex Pharmaceuticals, Inc. |
Injectable nitrogen mustard compositions comprising a cyclodextrin derivative and methods of making and using the same
|
CA2760284A1
(en)
|
2009-05-29 |
2010-12-02 |
Pfizer Limited |
Novel glucocorticoid receptor agonists
|
US8492538B1
(en)
|
2009-06-04 |
2013-07-23 |
Jose R. Matos |
Cyclodextrin derivative salts
|
EP2266563A1
(de)
|
2009-06-11 |
2010-12-29 |
Charité-Universitätsmedizin Berlin (Charité) |
Verwendung von Opiodrezeptorantagonisten zur akuten Behandlung von paraphilischen Erregungszuständen
|
EP2442791B1
(de)
|
2009-06-16 |
2019-11-27 |
Pfizer Inc. |
Darreichungsformen von apixaban
|
WO2011004276A1
(en)
|
2009-07-06 |
2011-01-13 |
Pfizer Limited |
Hepatitis c virus inhibitors
|
DE102009034368A1
(de)
|
2009-07-20 |
2011-01-27 |
Bayer Schering Pharma Aktiengesellschaft |
17-Hydroxy-17-pentafluorethyl-estra-4,9(10)-dien-11-acyloxyalkylenphenyl-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung zur Behandlung von Krankheiten
|
WO2011041593A1
(en)
*
|
2009-09-30 |
2011-04-07 |
University Of Kansas |
Novobiocin analogues and treatment of polycystic kidney disease
|
JP5919196B2
(ja)
|
2009-11-13 |
2016-05-18 |
オニキス セラピューティクス, インク.Onyx Therapeutics, Inc. |
転移抑制のためのペプチドエポキシケトンの使用
|
WO2011077313A1
(en)
|
2009-12-22 |
2011-06-30 |
Pfizer Inc. |
Piperidinecarboxamides as mpges - 1 inhibitors
|
UA107100C2
(xx)
|
2009-12-23 |
2014-11-25 |
|
Конденсовані гетероароматичні піролідинони як інгібітори syk
|
WO2011083387A1
(en)
|
2010-01-07 |
2011-07-14 |
Pfizer Limited |
Hydrochloride salt of biphenyl-2-yl-carbamic acid 1-{9-[(3-fluoro-4-hydroxy-benzoyl)-methyl-amino]-nonyl}-piperidin-4-yl ester
|
SI2525798T1
(en)
|
2010-01-21 |
2018-01-31 |
Drawbridge Pharmaceuticals Pty Ltd. |
Anesthetic formulation
|
GB201001688D0
(en)
|
2010-02-02 |
2010-03-17 |
Novacta Biosystems Ltd |
Compounds
|
MX2012008819A
(es)
|
2010-02-02 |
2012-09-28 |
Novacta Biosystems Ltd |
Sales de lantibioticos.
|
JP2013520489A
(ja)
|
2010-02-25 |
2013-06-06 |
ファイザー・リミテッド |
ペプチド類似体
|
CN102892417A
(zh)
|
2010-03-01 |
2013-01-23 |
欧尼斯治疗公司 |
用于免疫蛋白酶体抑制的化合物
|
AU2011228758A1
(en)
*
|
2010-03-13 |
2012-11-08 |
Eastpond Laboratories Limited |
Fat-binding compositions
|
CA2795559A1
(en)
|
2010-04-07 |
2011-11-03 |
Onyx Therapeutics, Inc. |
Crystalline peptide epoxyketone immunoproteasome inhibitor
|
CA2796967C
(en)
|
2010-05-04 |
2015-12-01 |
Pfizer Inc. |
Heterocyclic derivatives as alk inhibitors
|
WO2011149349A1
(en)
|
2010-05-26 |
2011-12-01 |
Neurophyxia B.V. |
2-iminobiotin formulations and uses thereof
|
WO2011154871A1
(en)
|
2010-06-10 |
2011-12-15 |
Pfizer Limited |
Hepatitis c virus inhibitors
|
EP2579869A2
(de)
*
|
2010-06-11 |
2013-04-17 |
Baxter International Inc |
Formulierungen mit amiodaron und salzen daraus sowie verfahren zu ihrer herstellung und verwendung
|
CA2804173C
(en)
|
2010-07-09 |
2015-01-13 |
Pfizer Limited |
Sulfonamide nav1.7 inhibitors
|
WO2012004714A2
(en)
|
2010-07-09 |
2012-01-12 |
Pfizer Limited |
Chemical compounds
|
EP2590951B1
(de)
|
2010-07-09 |
2015-01-07 |
Pfizer Limited |
Benzolsulfonamide als kaliumkanalhemmer
|
WO2012007877A2
(en)
|
2010-07-12 |
2012-01-19 |
Pfizer Limited |
Chemical compounds
|
WO2012007883A1
(en)
|
2010-07-12 |
2012-01-19 |
Pfizer Limited |
Sulfonamide derivatives as nav1.7 inhibitors for the treatment of pain
|
JP2013532184A
(ja)
|
2010-07-12 |
2013-08-15 |
ファイザー・リミテッド |
電位開口型ナトリウムチャネル阻害剤として有用なn−スルホニルベンズアミド誘導体
|
JP2013531030A
(ja)
|
2010-07-12 |
2013-08-01 |
ファイザー・リミテッド |
電位開口型ナトリウムチャネルの阻害剤としてのn−スルホニルベンズアミド
|
EP2593428B1
(de)
|
2010-07-12 |
2014-11-19 |
Pfizer Limited |
N-sulfonylbenzamide als inhibitoren von spannungsabhängigen natriumkanälen
|
GB201013509D0
(en)
|
2010-08-11 |
2010-09-22 |
Novacta Biosystems Ltd |
Compounds
|
GB201013508D0
(en)
|
2010-08-11 |
2010-09-22 |
Novacta Biosystems Ltd |
Compounds
|
GB201013513D0
(en)
|
2010-08-11 |
2010-09-22 |
Novacta Biosystems Ltd |
Formulations
|
GB201013507D0
(en)
|
2010-08-11 |
2010-09-22 |
Novacta Biosystems Ltd |
Compounds
|
WO2012025745A1
(en)
|
2010-08-24 |
2012-03-01 |
Imperial Innovations Limited |
Glycodendrimers of polypropyletherimine
|
WO2012042421A1
(en)
|
2010-09-29 |
2012-04-05 |
Pfizer Inc. |
Method of treating abnormal cell growth
|
EP2635273B1
(de)
|
2010-11-01 |
2020-01-08 |
MEI Pharma, Inc. |
Isoflavonoidzusammensetzungen und verfahren zur krebsbehandlung
|
RU2564445C2
(ru)
|
2010-11-15 |
2015-10-10 |
ВииВ Хелткер ЮКей Лимитед |
Ингибиторы репликации вич
|
WO2012095781A1
(en)
|
2011-01-13 |
2012-07-19 |
Pfizer Limited |
Indazole derivatives as sodium channel inhibitors
|
ES2672238T3
(es)
|
2011-01-26 |
2018-06-13 |
Allergan, Inc. |
Composición androgénica para el tratamiento de una afección oftálmica
|
JP5931933B2
(ja)
|
2011-02-25 |
2016-06-08 |
武田薬品工業株式会社 |
N−置換オキサジノプテリジンおよびオキサジノプテリジノン
|
WO2012120398A1
(en)
|
2011-03-04 |
2012-09-13 |
Pfizer Limited |
Aryl substituted carboxamide derivatives as trpm8 modulators
|
JP5595616B2
(ja)
|
2011-04-05 |
2014-09-24 |
ファイザー・リミテッド |
トロポミオシン関連キナーゼ阻害薬としてのピロロ[2,3−d]ピリミジン誘導体
|
BR112013029319A2
(pt)
|
2011-05-18 |
2017-01-31 |
Raqualia Pharma Inc |
forma polimorfa i de ácido 4-{[4-({[4-(2,2,2-trifluoroetoxi)-1,2-benzisoxazol-3-il]oxi}metil)piperidina-1-il]metil}-tetrahidro-2h-pirano-4 carboxílico, forma polimorfa ii de ácido 4-{[4-({[4-(2,2,2-trifluoroetoxi)-1,2-benzisoxazol-3-il]oxi}metil)piperidina-1-il]metil}-tetrahidro-2h-pirano-4 carboxílico, uso e processo, e método para tratar condições de doença mediadas por atividade receptora de 5-ht4
|
TWI544922B
(zh)
|
2011-05-19 |
2016-08-11 |
愛爾康研究有限公司 |
高濃度歐羅派特錠(olopatadine)眼用組成物
|
WO2012171561A1
(en)
|
2011-06-15 |
2012-12-20 |
Synthon Bv |
Stabilized voriconazole composition
|
EP2723739B1
(de)
|
2011-06-22 |
2016-08-24 |
Takeda Pharmaceutical Company Limited |
Substituierte 6-aza-isoindolin-1-on-derivate
|
ES2564366T3
(es)
|
2011-07-13 |
2016-03-22 |
Pfizer Limited |
Análogos de encefalina
|
US8575336B2
(en)
|
2011-07-27 |
2013-11-05 |
Pfizer Limited |
Indazoles
|
EP2739274A1
(de)
|
2011-08-02 |
2014-06-11 |
Pensieve Biosciences Cyprus Limited |
Behandlung von kognitiver störung
|
EP2739284A1
(de)
|
2011-08-02 |
2014-06-11 |
Pfizer Inc |
Crizotinib zur verwendung in der krebsbehandlung
|
SI2753632T1
(sl)
|
2011-09-08 |
2023-08-31 |
Sage Therapeutics, Inc. |
Nevroaktivni steroidi, njihovi sestavki in uporaba
|
US9376395B2
(en)
|
2011-09-18 |
2016-06-28 |
Purdue Pharmaceuticals Products L.P. |
Pharmaceutical compositions
|
WO2013054185A1
(en)
|
2011-10-13 |
2013-04-18 |
Pfizer, Inc. |
Pyrimidine and pyridine derivatives useful in therapy
|
CN108976272B
(zh)
|
2011-10-14 |
2021-05-25 |
萨奇治疗股份有限公司 |
3,3-二取代的19-去甲孕甾烷化合物、组合物、及其用途
|
JP5363636B2
(ja)
|
2011-10-21 |
2013-12-11 |
ファイザー・リミテッド |
新規な塩および医学的使用
|
CA2850925C
(en)
|
2011-10-26 |
2017-01-10 |
Pfizer Limited |
(4-phenylimidazol-2-yl) ethylamine derivatives useful as sodium channel modulators
|
US9273011B2
(en)
|
2011-10-28 |
2016-03-01 |
Inhibitaxin Limited |
Substituted pyridazines for the treatment of pain
|
ES2593533T3
(es)
|
2011-12-15 |
2016-12-09 |
Pfizer Limited |
Derivados de sulfonamida
|
WO2013093688A1
(en)
|
2011-12-19 |
2013-06-27 |
Pfizer Limited |
Sulfonamide derivatives and use thereof as vgsc inhibitors
|
TW201332572A
(zh)
|
2011-12-28 |
2013-08-16 |
Otsuka Pharma Co Ltd |
具有經取代的β-環糊精之藥物製劑
|
JP6067031B2
(ja)
|
2012-01-04 |
2017-01-25 |
ファイザー・リミテッドPfizer Limited |
N−アミノスルホニルベンズアミド
|
GB201201332D0
(en)
|
2012-01-26 |
2012-03-14 |
Imp Innovations Ltd |
Method
|
AR092790A1
(es)
|
2012-02-01 |
2015-05-06 |
Euro Celtique Sa |
Derivados bencimidazolicos del acido hidroxamico
|
JP6002785B2
(ja)
|
2012-02-03 |
2016-10-05 |
ファイザー・インク |
ナトリウムチャネルモジュレーターとしてのベンゾイミダゾールおよびイミダゾピリジン誘導体
|
TW201336527A
(zh)
|
2012-02-10 |
2013-09-16 |
Alcon Res Ltd |
具增強的穩定性之水性藥學組成物
|
PL3702374T3
(pl)
|
2012-02-15 |
2022-11-21 |
Cydex Pharmaceuticals, Inc. |
Sposób wytwarzania pochodnych cyklodekstryny
|
RU2747757C2
(ru)
|
2012-02-28 |
2021-05-13 |
Сидекс Фармасьютикалс, Инк. |
Композиции алкилированного циклодекстрина и способы их получения и применения
|
PL2822953T3
(pl)
|
2012-03-06 |
2017-07-31 |
Pfizer Inc. |
Makrocykliczne pochodne do leczenia chorób proliferacyjnych
|
WO2013148603A1
(en)
|
2012-03-27 |
2013-10-03 |
Takeda Pharmaceutical Company Limited |
Cinnoline derivatives as as btk inhibitors
|
US20150087822A1
(en)
|
2012-03-30 |
2015-03-26 |
Sapiotec Gmbh |
Anthocyanidin complex
|
TW201414751A
(zh)
|
2012-07-09 |
2014-04-16 |
歐尼克斯治療公司 |
肽環氧酮蛋白酶抑制劑之前驅藥物
|
TW201414734A
(zh)
|
2012-07-10 |
2014-04-16 |
Takeda Pharmaceutical |
氮雜吲哚衍生物
|
CN104684585A
(zh)
|
2012-08-03 |
2015-06-03 |
美国政府(由卫生和人类服务部的部长所代表) |
用于治疗溶酶体贮积症的环糊精
|
US9475816B2
(en)
|
2012-09-07 |
2016-10-25 |
Takeda Pharmaceutical Company Limited |
Substituted-1,4-dihydropyrazolo[4,3-b]indoles
|
WO2014045029A1
(en)
|
2012-09-18 |
2014-03-27 |
Ziarco Pharma Ltd |
2-(2-aminocyclohexyl)amino-pyrimidine-5-carboxamides as spleen tyrosine kinasei(syk) inhibitors
|
CA2884848C
(en)
|
2012-09-28 |
2017-08-22 |
Pfizer Inc. |
Benzamide and heterobenzamide compounds
|
US20140094432A1
(en)
|
2012-10-02 |
2014-04-03 |
Cerulean Pharma Inc. |
Methods and systems for polymer precipitation and generation of particles
|
JP2015531393A
(ja)
|
2012-10-04 |
2015-11-02 |
ファイザー・リミテッドPfizer Limited |
トロポミオシン関連キナーゼ阻害剤
|
CA2885259A1
(en)
|
2012-10-04 |
2014-04-10 |
Pfizer Limited |
Pyrrolo[3,2-c]pyridine tropomyosin-related kinase inhibitors
|
US20150218172A1
(en)
|
2012-10-04 |
2015-08-06 |
Pfizer Limited |
Pyrrolo[2,3-D]Pyrimidine Tropomyosin-Related Kinase Inhibitors
|
US20150258202A1
(en)
*
|
2012-10-17 |
2015-09-17 |
Sapiotec Gmbh |
Anthocyanidin complex for the treatment of multiple myeloma
|
CN105073785B
(zh)
|
2012-10-22 |
2018-08-21 |
锡德克斯药物公司 |
烷基化环糊精组合物及其制备和使用方法
|
SG11201502763VA
(en)
|
2012-11-08 |
2015-05-28 |
Pfizer |
Heteroaromatic compounds and their use as dopamine d1 ligands
|
EA201500402A1
(ru)
|
2012-11-08 |
2016-05-31 |
Пфайзер Инк. |
Гетероароматические соединения в качестве лигандов допамина d1
|
US9925274B2
(en)
*
|
2012-11-15 |
2018-03-27 |
Sapiotec Gmbh |
Delphinidin complex as an antiphlogistic or immunosuppressive active ingredient
|
CA2890861C
(en)
|
2012-11-21 |
2021-03-30 |
Raqualia Pharma Inc. |
Polymorphic forms of 4-{[4-({[4-(2,2,2-trifluoroethoxy)-1,2-benzisoxazol-3-yl]oxy}methyl)piperidin-1-yl]methyl}-tetrahydro-2h-pyran-4-carboxylic acid
|
MA38114A1
(fr)
|
2012-12-03 |
2017-12-29 |
Pfizer |
Nouveaux modulateurs androgéniques sélectifs
|
KR102164174B1
(ko)
*
|
2012-12-11 |
2020-10-12 |
자피오텍 게엠베하 |
흑색종 세포를 퇴치하기 위한 델피니딘
|
UA112028C2
(uk)
|
2012-12-14 |
2016-07-11 |
Пфайзер Лімітед |
Похідні імідазопіридазину як модулятори гамка-рецептора
|
UA111305C2
(uk)
|
2012-12-21 |
2016-04-11 |
Пфайзер Інк. |
Конденсовані лактами арилу та гетероарилу
|
RU2018145691A
(ru)
|
2013-01-23 |
2019-04-01 |
Альдейра Терапьютикс, Инк. |
Заболевания, связанные с токсичным альдегидом, и их лечение
|
EP3431475B1
(de)
|
2013-02-21 |
2021-04-07 |
Pfizer Inc |
Feste formen eines selektiven cdk4/6 inhibitors
|
JO3377B1
(ar)
|
2013-03-11 |
2019-03-13 |
Takeda Pharmaceuticals Co |
مشتقات بيريدينيل وبيريدينيل مندمج
|
PT3461834T
(pt)
|
2013-03-13 |
2021-09-10 |
Sage Therapeutics Inc |
Esteroides neuroativos
|
RU2021111681A
(ru)
|
2013-03-13 |
2021-05-11 |
Сейдж Терапьютикс, Инк. |
Нейроактивные стероиды, композиции и их применение
|
EP2784083A1
(de)
|
2013-03-28 |
2014-10-01 |
Charité - Universitätsmedizin Berlin |
Knochenmorphogenetische Protein (BMP)-Varianten mit hoch reduzierter Antagonisten-Sensibilität und erweiterter spezifischer biologischer Aktivität
|
KR20230172622A
(ko)
|
2013-04-17 |
2023-12-22 |
세이지 테라퓨틱스, 인크. |
19-노르 c3,3-이치환된 c21-n-피라졸릴 스테로이드 및 그의 사용 방법
|
EP2986624B1
(de)
|
2013-04-17 |
2020-03-25 |
Sage Therapeutics, Inc. |
Neuroaktive 19-nor-steroide zur verwendung zur behandlung von krankheiten
|
EP2792360A1
(de)
|
2013-04-18 |
2014-10-22 |
IP Gesellschaft für Management mbH |
(1aR,12bS)-8-cyclohexyl-11-fluoro-N-((1-methylcyclopropyl)sulfonyl)-1a-((3-methyl-3,8-diazabicyclo[3.2.1]oct-8-yl)carbonyl)-1,1a,2,2b-tetrahydrocyclopropa[d]indolo[2,1-a][2]benzazepine-5-carboxamide zur Verwendung bei der Behandlung von HCV
|
TW201443025A
(zh)
|
2013-04-19 |
2014-11-16 |
Pfizer Ltd |
化學化合物
|
TW201512171A
(zh)
|
2013-04-19 |
2015-04-01 |
Pfizer Ltd |
化學化合物
|
WO2014181213A1
(en)
|
2013-05-10 |
2014-11-13 |
Pfizer Inc. |
Crystalline form of (sa)-(-)-3-(3-bromo-4-((2,4-difluorobenzyl)oxy)-6-methyl-2-oxopyridin-1 (2h)-yl)-n,4-dimethylbenzamide
|
PT3013813T
(pt)
|
2013-06-27 |
2019-06-14 |
Pfizer |
Compostos heteroaromáticos e a sua utilização como ligandos de d1 de dopamina
|
SG11201600107RA
(en)
|
2013-07-08 |
2016-02-26 |
Abbvie Inc |
Stabilized pharmaceutical dosage forms comprising atrasentan
|
GB201312737D0
(en)
|
2013-07-17 |
2013-08-28 |
Univ Greenwich |
Cyclodextrin
|
PL3021852T3
(pl)
|
2013-07-19 |
2021-07-05 |
Sage Therapeutics, Inc. |
Neuroaktywne steroidy, kompozycje i ich zastosowania
|
CA3235088A1
(en)
|
2013-08-23 |
2015-02-26 |
Sage Therapeutics, Inc. |
Neuroactive steroids, compositions, and uses thereof
|
US8962675B1
(en)
|
2013-09-12 |
2015-02-24 |
Abbvie Inc. |
Atrasentan mandelate salts
|
CN104513253A
(zh)
|
2013-10-01 |
2015-04-15 |
南京波尔泰药业科技有限公司 |
用于治疗增殖性疾病的大环化合物
|
RU2572334C2
(ru)
*
|
2013-12-06 |
2016-01-10 |
Общество С Ограниченной Ответственностью "Луфатен" |
Клатратный комплекс арабиногалактана или гуммиарабика с 20-гидроксиэкдизоном, способ его получения (варианты), фармацевтическая композиция и лекарственное средство
|
WO2015092610A1
(en)
|
2013-12-20 |
2015-06-25 |
Pfizer Limited |
N-acylpiperidine ether tropomyosin-related kinase inhibitors
|
TW201620904A
(zh)
|
2014-01-09 |
2016-06-16 |
武田藥品工業有限公司 |
氮雜吲哚衍生物
|
WO2015106014A1
(en)
|
2014-01-09 |
2015-07-16 |
Takeda Pharmaceutical Company Limited |
Azaindole derivatives
|
CN104971355B
(zh)
*
|
2014-04-02 |
2018-04-24 |
上海现代药物制剂工程研究中心有限公司 |
含有利伐沙班的组合物及其制备方法
|
EP3131891A1
(de)
|
2014-04-15 |
2017-02-22 |
Pfizer Inc. |
Tropomysin-verwandte kinaseinhibitoren mit einer 1h-pyrazol- sowie pyrimidineinheit
|
AU2015249496A1
(en)
|
2014-04-25 |
2016-09-29 |
Pfizer Inc. |
Heteroaromatic compounds and their use as dopamine D1 ligands
|
WO2015162518A1
(en)
|
2014-04-25 |
2015-10-29 |
Pfizer Inc. |
Heteroaromatic compounds and their use as dopamine d1 ligands
|
JP6239149B2
(ja)
|
2014-04-25 |
2017-11-29 |
ファイザー・インク |
複素芳香族化合物およびそのドーパミンd1リガンドとしての使用
|
EP3137454A1
(de)
|
2014-04-28 |
2017-03-08 |
Pfizer Inc. |
Heteroaromatische verbindungen und deren verwendung als dopamin-d1-liganden
|
CA2946990A1
(en)
|
2014-04-28 |
2015-11-05 |
Pfizer Inc. |
Heterocyclic compounds and their use as dopamine d1 ligands
|
EP3140298A1
(de)
|
2014-05-07 |
2017-03-15 |
Pfizer Inc. |
Tropomyosin-assoziierte kinaseinhibitoren
|
MD20160121A2
(ro)
|
2014-05-14 |
2017-05-31 |
Pfizer Inc. |
Pirazolopiridine şi pirazolopirimidine
|
DK3143019T3
(da)
|
2014-05-15 |
2021-01-04 |
Pfizer |
Krystallinsk form af 6-[(4R)-4-methyl-1,2-dioxido-1,2,6-thiadiazinan-2-yl]isoquinolin-1-carbonitril
|
KR102471082B1
(ko)
|
2014-05-20 |
2022-11-25 |
라퀄리아 파마 인코포레이티드 |
벤즈이소옥사졸 유도체염
|
GB201409488D0
(en)
|
2014-05-28 |
2014-07-09 |
Euro Celtique Sa |
Pharmaceutical composition
|
GB201409471D0
(en)
|
2014-05-28 |
2014-07-09 |
Euro Celtique Sa |
Pharmaceutical composition
|
GB201409485D0
(en)
|
2014-05-28 |
2014-07-09 |
Euro Celtique Sa |
Pharmaceutical composition
|
ES2805598T3
(es)
|
2014-05-29 |
2021-02-12 |
Sage Therapeutics Inc |
Esteroides neuroactivos, composiciones y usos de los mismos
|
RU2016146826A
(ru)
|
2014-05-30 |
2018-07-04 |
Пфайзер Инк. |
Производные карбонитрилов как селективные модуляторы андрогенового рецептора
|
CA2950393A1
(en)
|
2014-05-30 |
2015-12-03 |
Pfizer Inc. |
Benzenesulfonamides useful as sodium channel inhibitors
|
US9802945B2
(en)
|
2014-06-12 |
2017-10-31 |
Pfizer Limited |
Imidazopyridazine derivatives as modulators of the GABAA receptor activity
|
WO2015193768A1
(en)
|
2014-06-17 |
2015-12-23 |
Pfizer Inc. |
Aryl fused lactams as ezh2 modulators
|
MY185765A
(en)
|
2014-06-17 |
2021-06-06 |
Pfizer |
Substituted dihydroisoquinolinone compounds
|
JP6628745B2
(ja)
|
2014-06-18 |
2020-01-15 |
セージ セラピューティクス, インコーポレイテッド |
オキシステロールおよびその使用方法
|
PL3166642T3
(pl)
|
2014-06-18 |
2020-11-30 |
Audevard |
Transdermalne preparaty pergolidu i ich zastosowanie
|
WO2016009296A1
(en)
|
2014-07-16 |
2016-01-21 |
Pfizer Inc. |
N-acylpiperidine ether tropomyosin-related kinase inhibitors
|
WO2016009303A1
(en)
|
2014-07-17 |
2016-01-21 |
Pfizer Inc. |
Pharmaceutical combinations comprising gabapentin or pregabalin with nav1.7 inhibitors
|
WO2016009297A1
(en)
|
2014-07-18 |
2016-01-21 |
Pfizer Inc. |
Pyridine derivatives as muscarinic m1 receptor positive allosteric modulators
|
WO2016020784A1
(en)
|
2014-08-05 |
2016-02-11 |
Pfizer Inc. |
N-acylpyrrolidine ether tropomyosin-related kinase inhibitors
|
EP3183295B1
(de)
*
|
2014-08-22 |
2023-08-02 |
CyDex Pharmaceuticals, Inc. |
Fraktionierte alkylierte cyclodextrinzusammensetzungen und verfahren zur herstellung und verwendung davon
|
WO2016034971A1
(en)
|
2014-09-04 |
2016-03-10 |
Pfizer Limited |
Sulfonamides derivatives as urat1 inhibitors
|
JOP20200195A1
(ar)
|
2014-09-08 |
2017-06-16 |
Sage Therapeutics Inc |
سترويدات وتركيبات نشطة عصبياً، واستخداماتها
|
WO2016044433A2
(en)
|
2014-09-16 |
2016-03-24 |
Biopharma Works |
Metformin derivatives
|
GB201417163D0
(en)
|
2014-09-29 |
2014-11-12 |
Provost Fellows & Scholars College Of The Holy Undivided Trinity Of Queen Elizabeth Near Dublin |
Substituted pyrimidine derivatives useful in the treatment of autoimmune diseases
|
GB201417165D0
(en)
|
2014-09-29 |
2014-11-12 |
Provost Fellows & Scholars College Of The Holy Undivided Trinity Of Queen Elizabeth Near Dublin |
Treatments for Autoimmune Disease
|
KR20170065637A
(ko)
|
2014-10-07 |
2017-06-13 |
세이지 테라퓨틱스, 인크. |
신경활성 화합물 및 그의 사용 방법
|
SI3206493T1
(sl)
|
2014-10-16 |
2020-10-30 |
Sage Therapeutics, Inc. |
Sestavki in metode za zdravljenje CNS motenj
|
AR102306A1
(es)
|
2014-10-16 |
2017-02-15 |
Sage Therapeutics Inc |
Esteroides neuroactivos útiles en el tratamiento de enfermedades del snc
|
WO2016067143A1
(en)
|
2014-10-28 |
2016-05-06 |
Pfizer Inc. |
N-(2-alkyleneimino-3-phenylpropyl)acetamide compounds and their use against pain and pruritus via inhibition of trpa1 channels
|
PL3224269T3
(pl)
|
2014-11-27 |
2020-08-24 |
Sage Therapeutics, Inc. |
Kompozycje i sposoby leczenia zaburzeń OUN
|
ES2746839T3
(es)
|
2014-12-18 |
2020-03-09 |
Pfizer |
Derivados de pirimidina y triazina y su uso como inhibidores de AXL
|
TW201636342A
(zh)
|
2014-12-19 |
2016-10-16 |
武田藥品工業有限公司 |
煙黴醇衍生物
|
US9765000B2
(en)
|
2015-01-22 |
2017-09-19 |
Phytoplant Research S.L. |
Methods of purifying cannabinoids, compositions and kits thereof
|
EP3613435A1
(de)
|
2015-01-28 |
2020-02-26 |
Universite De Bordeaux |
Inhibitoren des chemokinrezeptor cxcr4 zur behandlung und/oder vorbeugung chronisch obstruktiver lungenerkrankung
|
US10980774B2
(en)
|
2015-02-02 |
2021-04-20 |
Mei Pharma, Inc. |
Combination therapies
|
CA2973140A1
(en)
|
2015-02-06 |
2016-08-11 |
Marinus Pharmaceuticals, Inc. |
Intravenous ganaxolone formulations and their use in treating status epilepticus and other seizure disorders
|
DK3258939T3
(da)
|
2015-02-20 |
2022-12-12 |
Sage Therapeutics Inc |
Neuroaktive steroider, sammensætninger og anvendelser heraf
|
EA031895B1
(ru)
|
2015-02-24 |
2019-03-29 |
Пфайзер Инк. |
Замещенные нуклеозидные производные, полезные в качестве агентов против рака
|
CN107847609A
(zh)
|
2015-03-13 |
2018-03-27 |
恩多塞特公司 |
用于治疗疾病的缀合物
|
MX2017011966A
(es)
|
2015-03-19 |
2018-06-06 |
Cydex Pharmaceuticals Inc |
Composiciones que contienen silimarina y sulfoalquil eter ciclodextrina y metodos de uso de las mismas.
|
US20180311258A1
(en)
|
2015-04-10 |
2018-11-01 |
Sage Therapeutics, Inc. |
Compositions and methods for treating cns disorders
|
BR112017026287A2
(pt)
|
2015-06-10 |
2018-09-18 |
Vtesse Inc |
composições de hidroxipropil beta-ciclodextrina e métodos
|
SG10202002655VA
(en)
|
2015-07-06 |
2020-05-28 |
Sage Therapeutics Inc |
Oxysterols and methods of use thereof
|
LT3319611T
(lt)
|
2015-07-06 |
2021-05-10 |
Sage Therapeutics, Inc. |
Oksisteroliai ir jų naudojimo būdai
|
MA42409A
(fr)
|
2015-07-06 |
2018-05-16 |
Sage Therapeutics Inc |
Oxystérols et leurs procédés d'utilisation
|
WO2017007805A1
(en)
|
2015-07-09 |
2017-01-12 |
Gilead Sciences, Inc. |
Intravenous formulations of a late sodium current inhibitor
|
ES2823049T3
(es)
|
2015-07-31 |
2021-05-05 |
Pfizer |
Derivados de carbamato de 1,1,1-trifluoro-3-hidroxipropan-2-ilo y derivados de carbamato de 1,1,1-trifluoro-4-hidroxibutan-2-ilo como inhibidores de MAGL
|
AU2016311158A1
(en)
|
2015-08-21 |
2018-04-05 |
Aldeyra Therapeutics, Inc. |
Deuterated compounds and uses thereof
|
EP3386983A1
(de)
|
2015-12-10 |
2018-10-17 |
Pfizer Limited |
4-(biphen-3-yl)-1h-pyrazolo[3,4-c]pyridazin-derivate der formel (i) als gaba-rezeptormodulatoren zur verwendung bei der behandlung von epilepsie und schmerzen
|
PL3394045T3
(pl)
|
2015-12-24 |
2021-09-27 |
Takeda Pharmaceutical Company Limited |
Kokryształ, sposób jego wytwarzania i lek zawierający kokryształ
|
TWI726968B
(zh)
|
2016-01-07 |
2021-05-11 |
開曼群島商Cs醫藥技術公司 |
Egfr酪胺酸激酶之臨床重要突變體之選擇性抑制劑
|
WO2017119732A1
(en)
|
2016-01-08 |
2017-07-13 |
Samsung Electronics Co., Ltd. |
Electronic device and operating method thereof
|
CA3011201C
(en)
|
2016-01-15 |
2020-09-22 |
Pfizer Inc. |
6,7,8,9-tetrahydro-5h-pyrido[2,3-d]azepine dopamine d3 ligands
|
AU2017221435A1
(en)
|
2016-02-18 |
2018-09-06 |
Melinta Therapeutics, Inc. |
Oritavancin formulations
|
KR20180116416A
(ko)
|
2016-02-28 |
2018-10-24 |
알데이라 테라퓨틱스, 아이엔씨. |
사이클로덱스트린으로의 알레르기성 안질환의 치료
|
JP7112957B2
(ja)
|
2016-03-09 |
2022-08-04 |
ベイジン パーカンズ オンコロジー カンパニー リミテッド |
腫瘍細胞懸濁培養及び関連方法
|
JP7305352B2
(ja)
*
|
2016-03-31 |
2023-07-10 |
武田薬品工業株式会社 |
イソキノリニルトリアゾロン錯体
|
CA3019146C
(en)
|
2016-04-01 |
2024-03-26 |
Sage Therapeutics, Inc. |
Oxysterols and methods of use thereof
|
WO2017193046A1
(en)
|
2016-05-06 |
2017-11-09 |
Sage Therapeutics, Inc. |
Oxysterols and methods of use thereof
|
US11129823B2
(en)
|
2016-05-09 |
2021-09-28 |
Aldeyra Therapeutics, Inc. |
Combination treatment of ocular inflammatory disorders and diseases
|
US20190030170A1
(en)
*
|
2016-05-10 |
2019-01-31 |
Vireo Health LLC |
Cannabinoid formulations with improved solubility
|
CA2969295A1
(en)
|
2016-06-06 |
2017-12-06 |
Pfizer Inc. |
Substituted carbonucleoside derivatives, and use thereof as a prmt5 inhibitor
|
RS62222B1
(sr)
|
2016-07-07 |
2021-09-30 |
Sage Therapeutics Inc |
24-hidroksisteroli supstituisani na poziciji 11 za upotrebu u lečenju stanja povezanih sa nmda
|
JP7065825B2
(ja)
|
2016-07-11 |
2022-05-12 |
セージ セラピューティクス, インコーポレイテッド |
C7、c12、およびc16置換神経刺激性ステロイドおよびそれらの使用方法
|
DK3481845T3
(da)
|
2016-07-11 |
2023-11-27 |
Sage Therapeutics Inc |
C17, c20 og c21 substituerede neuroaktive steroider og deres anvendelsesmetoder
|
CA3031895A1
(en)
|
2016-07-29 |
2018-02-01 |
Pfizer Inc. |
Cyclic peptides as c5 a receptor antagonists
|
MX2019001669A
(es)
|
2016-08-11 |
2019-09-27 |
Ovid Therapeutics Inc |
Metodos y composiciones para el tratamiento de trastornos epilepticos.
|
MA45920B1
(fr)
|
2016-08-15 |
2021-08-31 |
Pfizer |
Inhibiteurs de pyridopyrimidinone cdk2/4/6
|
US10391105B2
(en)
|
2016-09-09 |
2019-08-27 |
Marinus Pharmaceuticals Inc. |
Methods of treating certain depressive disorders and delirium tremens
|
CN110023323A
(zh)
|
2016-09-30 |
2019-07-16 |
萨奇治疗股份有限公司 |
C7取代的氧固醇及其作为nmda调节剂的方法
|
AU2016426574B2
(en)
|
2016-10-11 |
2023-07-13 |
Euro-Celtique S.A. |
Hodgkin lymphoma therapy
|
MX2019004679A
(es)
|
2016-10-18 |
2019-10-15 |
Sage Therapeutics Inc |
Oxisteroles y metodos de uso de los mismos.
|
EP4252848A3
(de)
|
2016-10-18 |
2023-11-08 |
Sage Therapeutics, Inc. |
Oxysterole und verfahren zur verwendung davon
|
US20190365720A1
(en)
|
2016-11-18 |
2019-12-05 |
Aicuris Anti-Infective Cures Gmbh |
Novel formulations of amidine substituted beta-lactam compounds on the basis of modified cyclodextrins and acidifying agents, their preparation and use as antimicrobial pharmaceutical compositions
|
US10316021B2
(en)
|
2016-11-28 |
2019-06-11 |
Pfizer Inc. |
Heteroarylphenoxy benzamide kappa opioid ligands
|
WO2018118791A2
(en)
|
2016-12-20 |
2018-06-28 |
Oligomerix, Inc. |
Novel quinazolinones that inhibit the formation of tau oligomers and their method of use
|
WO2018133826A1
(zh)
|
2017-01-20 |
2018-07-26 |
深圳市塔吉瑞生物医药有限公司 |
用于抑制蛋白激酶活性的(杂)芳基酰胺类化合物
|
KR20190104405A
(ko)
|
2017-01-20 |
2019-09-09 |
화이자 인코포레이티드 |
Magl 억제제로서의 1,1,1-트리플루오로-3-히드록시프로판-2-일 카르바메이트 유도체
|
US11091462B2
(en)
|
2017-01-20 |
2021-08-17 |
Shenzhen Targetrx, Inc. |
(Hetero)arylamide compound for inhibiting protein kinase activity
|
EP3571202B1
(de)
|
2017-01-23 |
2021-06-30 |
Pfizer Inc. |
Heterocyclische spiro-verbindungen als magl-inhibitoren
|
WO2018146698A1
(en)
|
2017-02-07 |
2018-08-16 |
Biophore India Pharmaceuticals Pvt. Ltd. |
Improved method for the preparation of sulfobutylether beta cyclodextrin sodium
|
WO2018170476A1
(en)
|
2017-03-16 |
2018-09-20 |
Aldeyra Therapeutics, Inc. |
Polymorphic compounds and uses thereof
|
JP7142675B2
(ja)
|
2017-03-26 |
2022-09-27 |
武田薬品工業株式会社 |
Gpr6のモジュレーターとしてのピペリジニルおよびピペラジニル置換された複素芳香族カルボキサミド
|
WO2018177403A1
(zh)
|
2017-04-01 |
2018-10-04 |
成都优赛丽医药科技有限公司 |
1H-咪唑[4,5-h]喹唑啉类化合物作为蛋白激酶抑制剂
|
BR112019023074A2
(pt)
|
2017-05-03 |
2020-06-09 |
Cydex Pharmaceuticals Inc |
composição contendo ciclodextrina e bussulfano
|
GB201709406D0
(en)
|
2017-06-13 |
2017-07-26 |
Euro-Cletique S A |
Compounds for treating TNBC
|
GB201709402D0
(en)
|
2017-06-13 |
2017-07-26 |
Euro Celtique Sa |
Compounds for treating t-pll
|
GB201709403D0
(en)
|
2017-06-13 |
2017-07-26 |
Euro Celtique Sa |
Compounds for treating sarcoma
|
GB201709405D0
(en)
|
2017-06-13 |
2017-07-26 |
Euro Celtique Sa |
Compounds for treating ovarian cancer
|
JOP20180057A1
(ar)
|
2017-06-15 |
2019-01-30 |
Takeda Pharmaceuticals Co |
مركبات رابع هيدروبيريدو بيرازين والتي تعمل كمعدلات gpr6
|
BR112019027127A2
(pt)
|
2017-06-22 |
2020-07-07 |
Curadev Pharma Limited |
moduladores de sting humano de molécula pequena
|
JP7374496B2
(ja)
|
2017-06-26 |
2023-11-07 |
深▲チェン▼市塔吉瑞生物医薬有限公司 |
Bcl-2タンパク質を阻害するためのN-ベンゼンスルホニルベンズアミド系化合物、その組成物および使用
|
EP3626709A1
(de)
|
2017-06-26 |
2020-03-25 |
Shenzhen Targetrx, Inc. |
Indazolverbindung zur verwendung in der hemmung der kinaseaktivität, zusammensetzung und anwendung davon
|
US10675296B2
(en)
|
2017-07-11 |
2020-06-09 |
Gilead Sciences, Inc. |
Compositions comprising an RNA polymerase inhibitor and cyclodextrin for treating viral infections
|
EP3666774B1
(de)
|
2017-08-11 |
2022-05-11 |
Shengke Pharmaceuticals (Jiangsu) Ltd. |
1h-pyrazolo[4,3-h]chinazolinverbindung als proteinkinaseinhibitor
|
SG11202001847WA
(en)
|
2017-08-30 |
2020-03-30 |
Beijing Xuanyi Pharmasciences Co Ltd |
Cyclic di-nucleotides as stimulator of interferon genes modulators
|
WO2019042187A1
(zh)
|
2017-08-30 |
2019-03-07 |
深圳市塔吉瑞生物医药有限公司 |
一种氨基嘧啶类化合物及包含该化合物的组合物及其用途
|
CN110997637B
(zh)
|
2017-09-05 |
2022-09-27 |
保仕健生物科技(上海)有限公司 |
芳香类衍生物、其制备方法及其在医药上的应用
|
CN111201223A
(zh)
|
2017-09-11 |
2020-05-26 |
克鲁松制药公司 |
SHP2的八氢环戊二烯并[c]吡咯别构抑制剂
|
TW201920108A
(zh)
|
2017-09-25 |
2019-06-01 |
日商武田藥品工業有限公司 |
N-(氰基取代之苄基或吡啶基甲基)-3-羥基吡啶醯胺衍生物
|
AU2018348174A1
(en)
|
2017-10-10 |
2020-04-23 |
Aldeyra Therapeutics, Inc. |
Treatment of inflammatory disorders
|
US20210228596A1
(en)
|
2017-10-12 |
2021-07-29 |
Sage Therapeutics, Inc. |
Method of treating cns disorders with neurosteroids and gabaergic compounds
|
US20200291059A1
(en)
|
2017-12-08 |
2020-09-17 |
Sage Therapeutics, Inc. |
Compositions and methods for treating cns disorders
|
CN109369721A
(zh)
|
2017-12-21 |
2019-02-22 |
深圳市塔吉瑞生物医药有限公司 |
用于抑制激酶活性的芳基磷氧化物
|
CN109627263B
(zh)
|
2017-12-21 |
2022-05-20 |
深圳市塔吉瑞生物医药有限公司 |
用于抑制激酶活性的二苯氨基嘧啶类化合物
|
JP7076159B2
(ja)
|
2017-12-21 |
2022-05-27 |
深▲チェン▼市塔吉瑞生物医薬有限公司 |
新規抗ウイルス性ヌクレオシド系逆転写酵素阻害剤
|
EP3730503A4
(de)
|
2017-12-21 |
2021-05-05 |
Shenzhen TargetRx, Inc. |
Antivirale nukleosidische reverse-transkriptase-hemmer
|
BR112020012761A2
(pt)
|
2017-12-22 |
2021-02-17 |
Sage Therapeutics, Inc. |
composições e métodos para o tratamento de distúrbios do snc
|
MX2020006599A
(es)
|
2017-12-22 |
2020-11-06 |
Sage Therapeutics Inc |
Composiciones y metodos para el tratamiento de trastornos en el sistema nervioso central.
|
EP3737687A1
(de)
|
2018-01-12 |
2020-11-18 |
Sage Therapeutics, Inc. |
Aza-, oxa- und thia-pregnan-20-on-3.alpha.-ol-verbindungen zur verwendung bei der behandlung von zns-erkrankungen
|
AU2019211188A1
(en)
|
2018-01-29 |
2020-07-30 |
Phytoplant Research S.L. |
Methods of purifying cannabinoids using liquid:liquid chromatography
|
TW201942115A
(zh)
|
2018-02-01 |
2019-11-01 |
美商輝瑞股份有限公司 |
作為抗癌藥之經取代的喹唑啉和吡啶並嘧啶衍生物
|
TW201942116A
(zh)
|
2018-02-09 |
2019-11-01 |
美商輝瑞股份有限公司 |
作為抗癌劑之四氫喹唑啉衍生物
|
IL276998B2
(en)
|
2018-03-01 |
2024-02-01 |
Takeda Pharmaceuticals Co |
Piperidinyl-3-(aryloxy)propanamides and propanoates
|
US10538542B2
(en)
|
2018-03-15 |
2020-01-21 |
Pfizer Inc. |
Cyclopentane-based modulators of STING (stimulator of interferon genes)
|
CN110386944B
(zh)
|
2018-04-16 |
2021-10-29 |
深圳市塔吉瑞生物医药有限公司 |
用于抑制蛋白激酶活性的二(杂)芳基大环化合物
|
CN109970745B
(zh)
|
2018-04-16 |
2020-12-08 |
深圳市塔吉瑞生物医药有限公司 |
取代的吡咯并三嗪类化合物及其药物组合物及其用途
|
RU2762557C1
(ru)
|
2018-04-26 |
2021-12-21 |
Пфайзер Инк. |
Производные 2-аминопиридина или 2-аминопиримидина в качестве циклинзависимых ингибиторов киназы
|
JP2021525809A
(ja)
|
2018-05-30 |
2021-09-27 |
コンバート ファーマシューティカルズ エス.エー. |
プロドラッグおよびその医学的使用
|
EA202092974A1
(ru)
|
2018-06-01 |
2021-04-09 |
Байер Кропсайенс Лп |
Стабилизированная фунгицидная композиция, содержащая циклодекстрин
|
WO2019243823A1
(en)
|
2018-06-21 |
2019-12-26 |
Curadev Pharma Limited |
Azaheterocyclic small molecule modulators of human sting
|
CN110194772B
(zh)
|
2018-07-02 |
2022-04-05 |
深圳市塔吉瑞生物医药有限公司 |
用于抑制蛋白激酶活性的炔基(杂)芳环类化合物
|
CN110256408B
(zh)
|
2018-07-12 |
2022-03-22 |
深圳市塔吉瑞生物医药有限公司 |
一种二芳基吡唑化合物及包含该化合物的组合物及其用途
|
JP7162931B2
(ja)
|
2018-07-17 |
2022-10-31 |
深▲チェン▼市塔吉瑞生物医薬有限公司 |
キナーゼ活性を阻害するためのアルキニル(ヘテロ)芳香族化合物
|
KR20210033504A
(ko)
|
2018-07-19 |
2021-03-26 |
화이자 인코포레이티드 |
Magl 억제제로서 헤테로환형 스피로 화합물
|
EP3833660A4
(de)
|
2018-08-06 |
2022-05-11 |
Aldeyra Therapeutics, Inc. |
Polymorphe verbindungen und verwendungen davon
|
CN115869258A
(zh)
|
2018-09-25 |
2023-03-31 |
奥尔德拉医疗公司 |
用于治疗干眼病的调配物
|
WO2020076728A1
(en)
|
2018-10-08 |
2020-04-16 |
Takeda Pharmaceutical Company Limited |
SUBSTITUTED OXAZINOPTERIDINONES AS INHIBITORS OF mTOR
|
EP3845538B1
(de)
|
2018-10-10 |
2023-11-08 |
Shenzhen TargetRx, Inc. |
Dihydroimidazopyrazinonverbindung, zusammensetzungen damit und verwendungen davon
|
JP2022504607A
(ja)
|
2018-10-12 |
2022-01-13 |
セージ セラピューティクス, インコーポレイテッド |
Cns障害の処置において使用するための、10位において環式基で置換された神経刺激性ステロイド
|
BR112021007401A2
(pt)
|
2018-10-19 |
2021-08-03 |
Sage Therapeutics, Inc. |
esteroides neuroativos insaturados 9(11) e seus métodos de uso
|
US11142525B2
(en)
|
2018-11-15 |
2021-10-12 |
Pfizer Inc. |
Azalactam compounds as HPK1 inhibitors
|
PE20211592A1
(es)
|
2018-11-29 |
2021-08-18 |
Pfizer |
Pirazoles como moduladores de la hemoglobina
|
BR112021010996A2
(pt)
|
2018-12-05 |
2021-08-31 |
Sage Therapeutics, Inc. |
Esteroides neuroativos e seus métodos de uso
|
CN111285886B
(zh)
|
2018-12-06 |
2023-04-11 |
深圳市塔吉瑞生物医药有限公司 |
取代的吡唑并[1,5-a]吡啶化合物及包含该化合物的组合物及其用途
|
US11266662B2
(en)
|
2018-12-07 |
2022-03-08 |
Marinus Pharmaceuticals, Inc. |
Ganaxolone for use in prophylaxis and treatment of postpartum depression
|
JP7240032B2
(ja)
|
2018-12-21 |
2023-03-15 |
深▲チェン▼市塔吉瑞生物医薬有限公司 |
プロテインキナーゼ活性を阻害するためのアミノピリミジン系化合物
|
AU2019403415A1
(en)
|
2018-12-21 |
2021-07-08 |
Sage Therapeutics, Inc. |
3.alpha.-hydroxy-17.beta.-amide neuroactive steroids and compositions thereof
|
WO2020141224A1
(en)
|
2019-01-04 |
2020-07-09 |
Sq Innovation Ag |
Pharmaceutical compositions of furosemide and uses thereof
|
CN113301901B
(zh)
|
2019-01-14 |
2022-09-09 |
北京轩义医药科技有限公司 |
四唑啉酮取代的类固醇及其用途
|
SG11202107226VA
(en)
|
2019-01-23 |
2021-08-30 |
Pfizer |
Polymorph form of a monophosphate hydrate salt of a known tetrahydroisoquinoline derivative
|
JP7094456B2
(ja)
|
2019-01-31 |
2022-07-01 |
ファイザー・インク |
Cdk2阻害剤
|
US20220098204A1
(en)
|
2019-02-18 |
2022-03-31 |
Shenzhen Targetrx, Inc. |
Substituted fused aromatic ring derivative, composition and use thereof
|
JP7241435B2
(ja)
|
2019-02-27 |
2023-03-17 |
深▲チェン▼市塔吉瑞生物医薬有限公司 |
置換ピラゾール系化合物および該当化合物を含む組成物並びにその使用
|
TW202102498A
(zh)
|
2019-03-22 |
2021-01-16 |
日商武田藥品工業股份有限公司 |
作為ripk2 抑制劑之吡啶稠合咪唑及吡咯衍生物
|
US11786518B2
(en)
|
2019-03-26 |
2023-10-17 |
Aldeyra Therapeutics, Inc. |
Ophthalmic formulations and uses thereof
|
CN113993585A
(zh)
|
2019-03-27 |
2022-01-28 |
英矽智能科技知识产权有限公司 |
双环jak抑制剂及其用途
|
WO2020223255A1
(en)
|
2019-04-29 |
2020-11-05 |
Solent Therapeutics, Llc |
3-amino-4h-benzo[e][1,2,4]thiadiazine 1,1-dioxide derivatives as inhibitors of mrgx2
|
BR112021024033A2
(pt)
|
2019-05-31 |
2022-02-08 |
Sage Therapeutics Inc |
Esteroides neuroativos e suas composições
|
TWI778366B
(zh)
|
2019-06-06 |
2022-09-21 |
中國商北京泰德製藥股份有限公司 |
作為atr激酶抑制劑的2,4,6-三取代的嘧啶化合物
|
MX2021015848A
(es)
|
2019-06-27 |
2022-04-18 |
Sage Therapeutics Inc |
Composiciones y métodos para el tratamiento de trastornos del snc.
|
JP2022538301A
(ja)
|
2019-06-27 |
2022-09-01 |
セージ セラピューティクス, インコーポレイテッド |
Cns障害を治療するための組成物及び方法
|
EP3990469A1
(de)
|
2019-06-27 |
2022-05-04 |
Sage Therapeutics, Inc. |
Zusammensetzungen und verfahren zur behandlung von störungen des zentralen nervensystems
|
US11339159B2
(en)
|
2019-07-17 |
2022-05-24 |
Pfizer Inc. |
Toll-like receptor agonists
|
WO2021014415A2
(en)
|
2019-07-25 |
2021-01-28 |
Curadev Pharma Pvt. Ltd. |
Small molecule inhibitors of acetyl coenzyme a synthetase short chain 2 (acss2)
|
CA3145923A1
(en)
|
2019-08-05 |
2021-02-11 |
David Czekai |
Ganaxolone for use in treatment of status epilepticus
|
US20230000997A1
(en)
|
2019-08-06 |
2023-01-05 |
L.E.A.F. Holdings Group Llc |
Processes of preparing polyglutamated antifolates and uses of their compositions
|
JP2022546375A
(ja)
|
2019-08-23 |
2022-11-04 |
北京泰徳製薬股▲フン▼有限公司 |
Egfrおよびalkを阻害してそれらの分解を阻害する化合物
|
CR20220160A
(es)
|
2019-09-16 |
2022-06-16 |
Takeda Pharmaceuticals Co |
Derivados de piridazin-3(2h)-ona fusionados con azol
|
EP4034534A1
(de)
|
2019-09-25 |
2022-08-03 |
Pfizer Inc. |
Polyheterocyclische modulatoren von sting (stimulator von interferongenen)
|
AU2020355359B2
(en)
|
2019-09-26 |
2023-08-24 |
Shenzhen Targetrx, Inc. |
Substituted aromatic fused ring derivative and composition comprising same, and use thereof
|
EP4056570A4
(de)
|
2019-11-01 |
2023-12-20 |
ShanghaiTech University |
Eed-inhibitor und herstellungsverfahren dafür sowie verwendung davon
|
JP2023503928A
(ja)
|
2019-12-06 |
2023-02-01 |
マリナス ファーマシューティカルズ, インコーポレイテッド |
結節性硬化症の治療での使用のためのガナキソロン
|
WO2021121261A1
(zh)
|
2019-12-16 |
2021-06-24 |
北京泰德制药股份有限公司 |
抑制并诱导降解egfr激酶的化合物
|
US20230122967A1
(en)
|
2020-01-17 |
2023-04-20 |
Shengke Pharmaceuticals (Jiangsu) Ltd. |
Novel compounds as inhibitors of pcsk9
|
KR20220141328A
(ko)
|
2020-02-12 |
2022-10-19 |
큐라데브 파마 프라이버트 리미티드 |
소분자 sting 길항제
|
AU2021238346A1
(en)
|
2020-03-18 |
2022-09-29 |
Sage Therapeutics, Inc. |
Neuroactive steroids and their methods of use
|
AR121683A1
(es)
|
2020-03-31 |
2022-06-29 |
Takeda Pharmaceuticals Co |
Derivados de n-heteroarilalquil-2-(heterociclil y heterociclilmetil)acetamida como agonistas de sstr4
|
AR121682A1
(es)
|
2020-03-31 |
2022-06-29 |
Takeda Pharmaceuticals Co |
Derivados de n-(heterociclil y heterociclilalquil)-3-bencilpiridin-2-amina como agonistas de sstr4
|
JP2021167301A
(ja)
|
2020-04-08 |
2021-10-21 |
ファイザー・インク |
Cdk2阻害剤に対する腫瘍適応を抑制するためのcdk4/6およびcdk2阻害剤による同時処置
|
MX2022013401A
(es)
|
2020-05-01 |
2022-11-14 |
Pfizer |
Compuestos de azalactama como inhibidores de hpk1.
|
US20230158010A1
(en)
|
2020-05-04 |
2023-05-25 |
Tony S. Gibson |
Luminally-acting n-(piperidin-4-yl)benzamide derivatives
|
WO2021224818A1
(en)
|
2020-05-08 |
2021-11-11 |
Pfizer Inc. |
Isoindolone compounds as hpk1 inhibitors
|
JP2023528289A
(ja)
|
2020-05-20 |
2023-07-04 |
北京泰徳製薬股▲フン▼有限公司 |
Atrキナーゼ阻害剤としての2,4,6-トリ置換ピリミジン化合物
|
IL299176A
(en)
|
2020-06-24 |
2023-02-01 |
Sage Therapeutics Inc |
Neuroactive steroids converted to 3.alpha.-hydroxy, 17.beta.-C-(O)-N-aryl and their compounds
|
TW202214641A
(zh)
|
2020-06-30 |
2022-04-16 |
美商艾瑞生藥股份有限公司 |
Her2突變抑制劑
|
US20230271968A1
(en)
|
2020-07-13 |
2023-08-31 |
Beijing Tide Pharmaceutical Co., Ltd. |
Pyrazolopyrimidine compound used as atr kinase inhibitor
|
US20230242539A1
(en)
|
2020-07-15 |
2023-08-03 |
Pfizer Inc. |
Polymorphs of (1S,2S,3S,5R)-3-((6-(Difluoromethyl)-5-Fluoro-1,2,3,4-Tetrahydroisoquinolin-8-YL)OXY)-5-(4-Methyl-7H-Pyrrolo[2,3-D]Pyrimidin-7-YL)Cyclopentane-1,2-DIOL Mono-Hydrochloride
|
WO2022013691A1
(en)
|
2020-07-15 |
2022-01-20 |
Pfizer Inc. |
Polymorph of (1s,2s,3s,5r)-3-((6-(difluoromethyl)-5-fluoro-1,2,3,4-tetrahydroisoquinolin-8-yl)oxy)-5-(4-methyl-7h-pyrrolo[2,3-d]pyrimidin-7-yl)cyclopentane-1,2-diol
|
WO2022018667A1
(en)
|
2020-07-24 |
2022-01-27 |
Pfizer Inc. |
Combination therapies using cdk2 and cdc25a inhibitors
|
GB202011811D0
(en)
|
2020-07-29 |
2020-09-09 |
Provost Fellows Found Scholars And The Other Members Of Board Of The College Of The Holy And Undivid |
Compounds
|
GB202011812D0
(en)
|
2020-07-29 |
2020-09-09 |
Provost Fellows Found Scholars And The Other Members Of Board Of The College Of The Holy And Undivid |
Compounds
|
JP2023538774A
(ja)
|
2020-08-27 |
2023-09-11 |
晟科薬業(江蘇)有限公司 |
新規な選択的flt3阻害剤としての1h-イミダゾ[4,5-h]キナゾリン化合物
|
TW202229239A
(zh)
|
2020-09-23 |
2022-08-01 |
日商武田藥品工業股份有限公司 |
作為ripk2抑制劑之3-(6-胺基吡啶-3-基)苯甲醯胺衍生物
|
CA3202870A1
(en)
|
2020-11-25 |
2022-06-02 |
Sage Therapeutics, Inc. |
Compositions and methods for treating cns disorders
|
US11964978B2
(en)
|
2021-03-18 |
2024-04-23 |
Pfizer Inc. |
Modulators of STING (stimulator of interferon genes)
|
JP2024512979A
(ja)
|
2021-03-31 |
2024-03-21 |
セブンレス セラピューティクス リミテッド |
疼痛の新しい処置
|
GB202104609D0
(en)
|
2021-03-31 |
2021-05-12 |
Sevenless Therapeutics Ltd |
New Treatments for Pain
|
AU2022255073A1
(en)
|
2021-04-07 |
2023-11-23 |
Lifearc |
2,4-diaminopyrimidine derivatives as ulk1/2 inhibitors and their use thereof
|
US11649299B2
(en)
|
2021-06-10 |
2023-05-16 |
Cyclolab Cyclodextrin Research And Development Laboratory Ltd. |
Purification of sulfobutylated cyclodextrins with specific ion exchange resins
|
AU2022297733A1
(en)
|
2021-06-26 |
2024-01-04 |
Array Biopharma Inc. |
Her2 mutation inhibitors
|
KR20240037975A
(ko)
|
2021-07-28 |
2024-03-22 |
세이지 테라퓨틱스, 인크. |
신경활성 스테로이드의 결정질 형태
|
IL310679A
(en)
|
2021-08-11 |
2024-04-01 |
Curadev Pharma Pvt Ltd |
Urea history of small molecules as STING antagonists
|
KR20240046742A
(ko)
|
2021-08-11 |
2024-04-09 |
큐라데브 파마 프라이버트 리미티드 |
소분자 sting 길항제
|
WO2023049295A1
(en)
|
2021-09-22 |
2023-03-30 |
Sage Therapeutics, Inc. |
Deuterated positive nmda-modulating compounds and methods of use thereof
|
WO2023099072A1
(en)
|
2021-12-01 |
2023-06-08 |
Fundación Del Sector Público Estatal Centro Nacional De Investigaciones Oncológicas Carlos III (F.S.P. CNIO) |
Compounds
|
WO2023144692A1
(en)
*
|
2022-01-25 |
2023-08-03 |
Leiutis Pharmaceuticals Llp |
Novel naproxen sodium preparations for parenteral
|
US11958917B2
(en)
|
2022-02-18 |
2024-04-16 |
Beren Therapeutics P.B.C. |
Compositions of hydroxypropyl-beta-cyclodextrin and methods of purifying the same
|
WO2023187677A1
(en)
|
2022-03-30 |
2023-10-05 |
Takeda Pharmaceutical Company Limited |
N-(pyrrolidin-3-yl or piperidin-4-yl)acetamide derivatives
|
WO2023194964A1
(en)
|
2022-04-07 |
2023-10-12 |
Takeda Pharmaceutical Company Limited |
Fused pyridazine derivatives as nlrp3 inhibitors
|
WO2023205165A1
(en)
*
|
2022-04-22 |
2023-10-26 |
Brii Biosciences Offshore Limited |
A polymyxin composition and methods for producing the same
|
EP4332087A1
(de)
|
2022-04-29 |
2024-03-06 |
Beijing Jitai Pharmaceutical Technology Co., Ltd. |
Lipidnanopartikel
|
CN116969851A
(zh)
|
2022-04-29 |
2023-10-31 |
北京剂泰医药科技有限公司 |
可电离脂质化合物
|
WO2024026337A1
(en)
|
2022-07-27 |
2024-02-01 |
Sage Therapeutics, Inc. |
Crystalline forms of a neuroactive steroid
|
WO2024023727A1
(en)
|
2022-07-29 |
2024-02-01 |
Pfizer Inc. |
Novel acc inhibitors
|
WO2024033845A1
(en)
|
2022-08-10 |
2024-02-15 |
Takeda Pharmaceutical Company Limited |
Heterocyclic compound
|
WO2024059608A1
(en)
|
2022-09-15 |
2024-03-21 |
Sage Therapeutics, Inc. |
Deuterated neuroactive steroids
|
WO2024074827A1
(en)
|
2022-10-05 |
2024-04-11 |
Sevenless Therapeutics Limited |
New treatments for pain
|